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ABSTRACT OF DISSERTATION

PERIPHERAL AND CENTRAL GLUCOSE FLUX IN TYPE I DIABETES

Diabetes is a complex metabolic disorder, of which high blood glucose
concentration is the primary hallmark. Type I diabetes mellitus (T1DM) is characterized
by the lack of insulin production, due to a poorly understood autoinflammatory cascade.
In the words of historian Barnett “Diabetes may no longer be a death sentence, but for
more and more people in the 21st century, it will become a life sentence”, making it the
focal point of many research groups. It is estimated that around 20 million individuals
worldwide live with T1DM.
Effects of long-term chronically elevated blood glucose are not only seen in
micro/macro-vascular diseases, retinopathy, peripheral neuropathy, and liver disease but
also in the brain as people with T1DM show decreased mental speed and flexibility.
Despite these clinical observations, the brain’s role in hyperglycemia remains to be
elucidated and could be key to identifying potential insulin-independent interventions to
alleviate these effects.
In recent years, insulin-independent mechanisms involved in glucose homeostasis
have been discovered, most notably the brain’s capacity to regulate blood glucose. The
brainstem dorsal vagal complex (DVC) is the main neuronal center responsible for
parasympathetic visceral regulation and has been identified as a microcircuit that is
important for the regulation of blood glucose. The present work, utilizing a designer
receptor exclusively activated by the designer drug (DREADDs) system to selectively
activate GABA neurons within hindbrain circuitry in vivo, demonstrates hindbrain inhibitory
microcircuitry as a key mediator of whole-body glucose levels, indicating the role of the
parasympathetic nervous system.
Neuronal function is affected by the brain metabolome, especially as glucose
metabolism is highly heterogeneous among brain regions. To accurately capture
physiological brain metabolome we developed a method utilizing a high-power focused
microwave to euthanize animals, and fix and preserve metabolites. To understand how
hyperglycemia modulates the central carbon metabolism of several brain regions
(neocortex, hippocampus, and dorsal vagal complex) we employed gas chromatographymass spectroscopy. Utilizing untargeted metabolomics we found that glucose
concentration was significantly elevated across all regions but glycogen and glucose-6phosphate remained unchanged with hyperglycemia only in DVC. Interestingly pyruvate
and lactate were unchanged across all regions indicating that hyperglycemia does not
affect anaerobic cellular respiration. Intermediates of the tricarboxylic acid (TCA) malate

and fumarate are significantly decreased with hyperglycemia only in DVC, suggesting that
hyperglycemia in DVC preferentially affects TCA cycle. Furthermore, we observed a
significant decrease in glutamate across all regions while glutamine and GABA were
unchanged, suggesting neurotransmitter regulation disturbance. Stable isotopic tracing of
uniformly labeled 13C6 glucose was employed to assess carbon flux in different brain
regions perturbed by T1DM to understand its effect on glycolysis, tricarboxylic acid cycle,
and neurotransmitter synthesis. We found that hyperglycemia results in metabolic
reprogramming with a significant decrease in glucose utilization and we demonstrated
decrease in immunofluorescent labeling of GLUT2, a neuronal glucose transporter, as
well as enzymes pyruvate dehydrogenase and pyruvate carboxylase, responsible for
anaplerosis of TCA cycle intermediates, indicating glucose hypometabolism phenotype.
This work is the first of its kind to demonstrate the effects of hyperglycemia not on
the brain as a whole but rather on specific regions; neocortex, hippocampus and DVC.
We shown heterogeneous effects of hyperglycemia on the central carbon metabolism
pathways in the brain, where TCA cycle and neurotransmitter regulation are selectively
affected in the DVC. Collectively, these data demonstrate that peripheral hyperglycemia
results in glucose hypometabolism in the brain and will serve as a starting point in
understanding the brain’s metabolic adaptations during hyperglycemia.
KEYWORDS: Type I diabetes (T1DM), hyperglycemia, glucose hypometabolism, 13C6
glucose tracer, dorsal vagal complex, brain
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CHAPTER 1. INTRODUCTION
1.1

Glucose homeostasis
Glucose is a six-carbon monosaccharide, a simple sugar that is obtained from food

sources and has two main roles: (a) a primary metabolic fuel and (b) the necessary
substrate for biosynthesis of all major classes of biomolecules [1]. Glucose levels are
tightly regulated and kept within a narrow physiological range. Low levels of blood sugar
called hypoglycemia can quickly result in a coma and be fatal if not treated. High levels of
blood glucose called hyperglycemia are not as acute of a concern but left untreated it will
lead to severe complications.
Glucose homeostasis is a multi-organ task, conventionally presented as primarily
orchestrated by counterbalancing the effects of two peptide hormones: insulin and
glucagon. After a meal, glucose-sensing cells in the pancreas trigger the release of insulin,
which results in the mobilization of insulin-dependent glucose receptors to the plasma
membrane and glucose uptake into the cells. Furthermore, the rise in insulin concentration
also inhibits gluconeogenesis, the endogenous glucose production by the liver. The
largest reservoir of glucose in the body is in the liver and skeletal muscle in the form of
glycogen. Upon a period of fasting, glucose sensing cells in the pancreas respond to low
levels of circulating glucose in the bloodstream and trigger the release of glucagon, which
results in glycogenolysis, the breakdown of glycogen and production of glucose from a
short-term storage form.
In contrast to the canonical view of two hormones balancing glucose homeostasis
in recent years, we have come to appreciate insulin-independent mechanisms involved in
glucose homeostasis [2–7], most notably the brain’s capacity to regulate blood glucose
[8–15]. More about the brain’s role will be discussed in subsequent sections.
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1.2

Uptake of glucose
Glucose is an obligatory metabolite for all cells and must be up taken into the cell

via facilitated diffusion or through sodium co-transport [16]. Pharmacological inhibition of
glucose transporters results in a decrease of glucose in the brain to less than a 5% of predrug treatment values, suggesting that glucose transporters are responsible for more than
95% of all glucose transfer across the blood-brain barrier (BBB) [17]. Furthermore, the
importance of glucose transporters in the brain is highlighted by conditions like glucose
transporter 1 (GLUT1) deficiency syndrome which leads to severe deterioration of brain
metabolism in addition to seizures and delayed development [18].
Human and canine experiments show that upon ingestion of an oral glucose load
under normal conditions about 1/3 is extracted by the liver, 1/3 by muscle and fat and 1/3
by red blood cells and the brain [19]. Glucose transporters play a crucial role in supplying
glucose to the brain. The demand for glucose in the brain is not constant and it changes
in response to brain activity [20]. In order to enter the brain, glucose must be translocated
across the BBB. That is accomplished by the high-affinity GLUT1 transporter expressed
in endothelial cells. The main driving force for GLUT1-mediated glucose uptake is the
concentration gradient, plasma glucose concentration is about 4-6mM, while brain
interstitial glucose concentration is 1-2 mM as measured by microdialysis [21]. In addition
to GLUT1-mediated glucose uptake in the brain, there are other GLUT transporters, but
we will only focus on GLUT1 and three other GLUT transporters. GLUT2 is a low-affinity
glucose transporter found in hepatocytes, the pancreas, and the brain. It has been shown
that GLUT2 together with glucokinase (GCK) serves as a glucose sensor [22]. In the brain,
GLUT2 has been shown to be localized across multiple brain cell types, including neurons
and glia [23–27]. GLUT3 is expressed in the brain and predominantly in neurons [16].
GLUT4 is an insulin-sensitive glucose transporter, meaning its insertion onto the plasma
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membrane is regulated by insulin concentration and plays a vital role in glucose
homeostasis. GLUT4 is most abundantly expressed in adipose tissue, skeletal muscle,
and the heart, but its presence has also been shown in the brain [16].

1.3

Central Carbon Metabolism
Glucose is crucial in many cellular processes, including adenosine 5’-triphosphate

(ATP) production, oxidative stress management, and synthesis of neurotransmitters and
neuromodulators. Catabolism of glucose through the process of glycolysis, tricarboxylic
acid cycle (TCA), and subsequent oxidative phosphorylation results in the generation of
ATP, the cell's energy currency. The major energy demand in the brain is for neuronal
signaling, including resting membrane potential, action potential generation, and
glutamate cycling to name a few [28]. The other major role of glucose is in terms of
anabolism and being a building block. Therefore, the simplest way to define central carbon
metabolism would be as a series of reactions that transforms carbon, including glycolysis,
gluconeogenesis, the pentose pathway and the TCA cycle (Fig 1.1).

3

Figure 1.1 Schematic of central carbon metabolism

1.3.1

Glycolysis, TCA cycle and neurotransmitters
After uptake of glucose into the brain via GLUT transporter, glucose

phosphorylation into glucose-6-phosphate (G6P) is the first irreversible step of glycolysis,
trapping the glucose inside of the cell [29]. G6P is the central hub for carbohydrate
metabolism as it has many possible fates (progression through glycolysis, entry into
pentose phosphate pathway, glycogen synthesis, hexosamine pathway, or glucose
production) [30]. The main end product of glucose oxidation through glycolysis is pyruvate,
which then enters into the TCA cycle.
The product of glycolysis, pyruvate is first converted to acetyl coenzyme A (acetylCoA), and then it enters into the TCA cycle. Through several steps and by utilizing
enzymes, the TCA cycle not only oxidizes carbohydrates, proteins and fats buy also
produces several intermediates which play a central role in processes like
gluconeogenesis, lipolysis, and neurotransmitter synthesis [31]. Carbons from glucose are
metabolized to acetyl-CoA via pyruvate dehydrogenase (PDH) or to oxaloacetate via
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pyruvate carboxylase (PC) [32], which are the two main ways for replenishment of TCA
cycle intermediates.
Neurotransmitters are responsible for the transfer of signals between neurons and
other cells. Glucose-derived neurotransmitters include acetylcholine, glutamate, and
GABA [28].
1.3.2

Key enzymes

1.3.2.1 Pyruvate Dehydrogenase (PDH)
Upon release of pyruvate from glycolysis, PDH is responsible for its conversion
into acetyl-CoA. The PDH-catalyzed reaction is necessary for oxidation of glucose, and
generation of ATP [33].
1.3.2.2 Pyruvate Carboxylase (PC)
Oxaloacetate is generated from pyruvate via PC. Early work on cell culture showed
that PC is expressed exclusively in astrocytes and not neurons [34–36], however, Hassel
and Brathe have shown that neuron pyruvate carboxylation occurs at a substantial rate
[37]. PC is critical for anaplerosis of the TCA cycle intermediates and therefore
gluconeogenesis and fatty acid synthesis.

1.4

Diabetes
Diabetes is a complex metabolic disorder, of which high blood glucose

concentration or hyperglycemia is the primary hallmark. The American Diabetes
Association characterizes Type I diabetes mellitus (T1DM) by a lack of insulin, while type
II (T2DM) is characterized by resistance to insulin [38]. T1DM is a result of loss in beta
cells (-cells) of the pancreas. The cause of the autoinflammatory cascades that destroy
pancreatic beta cells remains to be fully understood (for a complete review of the current
5

understanding of autoimmune cascades that result in loss of insulin producing -cells see
[39]). T1DM is considered one of the most common disorders occurring affecting children
[39]. In the words of historian Barnett “Diabetes may no longer be a death sentence, but
for more and more people in the 21st century, it will become a life sentence”, making it the
focal point of many research groups [40]. It is estimated that around 1.2 million people
under the age of 20 worldwide live with T1DM [41].
The first mentions of the disease with symptoms of frequent urination and a sweet
taste of urine are as old as 2000BC. Before modern capacities of metabolomics, ancient
Chinese doctors described utilizing ants to evaluate the urine with high content of glucose,
as ants were attracted to sweet urine [42–44]. Today, diabetes is diagnosed when fasting
blood glucose levels are above 125 mg/dL, or if levels are above 200mg/dL at any point
in the day [45].
1.4.1

Effects of Hyperglycemia on Peripheral Tissue

1.4.1.1 Liver
The liver is the metabolic hub of the human body and is exposed to higher nutrient
levels than any other peripheral tissue [46]. Its role is vital in metabolism due to its unique
task as the gatekeeper of glucose storage, release, and redistribution, keeping the levels
of glucose between fed and fasted states in a narrow range. Entry of glucose into the
portal vein stimulates net hepatic glucose uptake and hepatic glycogen synthesis but not
whole-body glucose clearance [47–49].
As mentioned earlier, in healthy individuals, intake of food will result in modest
hyperglycemia and an increase in glycogen production in the liver. In individuals with
poorly controlled T1DM intake of food results in drastic hyperglycemia and impaired
hepatic glycogen accumulation [50–53]. Furthermore, patients with T1DM and T2DM as
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well as animal models show increased hepatic glucose production [54–57]. It has been
shown that without glucose stimulation, glucokinase (GCK) sequesters in the nucleus of
hepatocytes where it is bound to a regulatory protein. Upon stimulation, GCK dissociates
from the regulatory protein, enters the cytosol, and catalyzes the phosphorylation of
glucose in hepatocytes [58,59]. Furthermore, data shows GCK suppression by 60% in
diabetics patients [60]. Other groups have shown decreases in animal models in GCK,
phosphofructokinase and pyruvate kinase activity [61]. T1DM also results in impaired
hepatic glycogenolysis, the breakdown of glycogen [53,62]. Hepatic glycolytic activity is
greatly affected by hyperglycemia as hepatic glycolytic flux is only 40% of the vehicletreated hepatocytes, and glucose cycling is twice the rate of that in vehicle-treated
hepatocytes [63]. Hepatic pyruvate metabolism in diabetes is also disturbed as pyruvate
is being utilized for gluconeogenesis rather than energy generation through ATP and
oxidative phosphorylation; thus the TCA cycle is greatly affected [64].
1.4.1.2 Skeletal Muscle
In a healthy individual, excess glucose after digestion is uptaken by liver which
results in inhibition of muscle glucose uptake [19]. Patient biopsy and [3-3H] glucose
infusion suggests accumulation of free glucose in the muscle [68]. Furthermore, it has
been shown that hyperglycemia increases the expression and activity of glutamine
synthetase, leading to accelerated glutamine production in skeletal muscle [69]. Because
insulin is necessary for muscle protein turnover [65,66], insulin deficiency results in
profound changes in mitochondrial function as measured by proteomics, specifically
mitochondrial uncoupling, lower ATP production, compromised cellular energy status, and
greater ROS emission in the muscle [67]. While insulin deficiency results in increased
protein synthesis in the splenic region, insulin deficiency does not affect protein synthesis
levels in muscle [66]. Metabolomic study of skeletal muscle in patients revealed profound
7

effects of T1DM on several key metabolic pathways like glycolysis and gluconeogenesis,
Krebs cycle, lipid metabolism and immune response [70].
1.4.2

Effects of Hyperglycemia on the Brain
Glucose is the preferred energy substrate of the brain [20]. To prevent possible

toxicity of glucose, the brain’s glucose levels are kept at about 20% of that of plasma.
Glucose availability in the brain is critical for the proper function of neurons, as glucose
demand increases following neuronal signaling [71].
Effects of chronically elevated blood glucose are not only seen in micro/macrovascular diseases, retinopathy, peripheral neuropathy, and liver disease but also in the
brain, as people with T1DM show decreased mental speed and flexibility [39,72,73]. Given
those results, neuroanatomical studies were carried out utilizing structural magnetic
resonance to investigate how hyperglycemia affects the brain, and it was found that in
children, hyperglycemia regionally alters gray matter volume, where decreased gray
matter volume was reported in bilateral occipital and cerebellar regions, while increased
gray matter volume was found in inferior prefrontal, insula, and temporal pole regions [74].
However, brainstem regions were not studied.
Regarding glucose uptake/transport, the experiments using radiatively labeled
glucose in animal models have divergent results; therefore, it is ambiguous whether
glucose transport across the BBB is affected by hyperglycemia. The difference in results
could be due to differences in methodology (i.e. length of hyperglycemia and
measurement in conscious vs. unconscious animals). Some groups reported a decrease
in glucose transport with hyperglycemia [75–78], while others reported no change [79,80].
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1.5

Brain Glucose Regulation
As described by Stubbs et al., the first evidence of brain glucose regulation was

presented by Dr. Claude Bernard in 1854 when he reported that a lesion in the floor of the
fourth ventricle in rabbits altered blood glucose levels [81]. As mentioned earlier, diabetes
decreases glucose clearance and induces insulin resistance in the muscle tissue, but that
only accounts for about 10% of the dysfunctional glucose clearance observed in diabetes
in muscle [83,84]. Therefore, decreased glucose clearance seems to be the culprit of failed
central metabolism. Since the 19th century, the body of knowledge about the brain's
glucoregulatory role has steadily increased. Several lines of evidence have emerged
suggesting the brain has two main roles in glucose regulation; 1) coordinate the magnitude
and timing of insulin response [85] and 2) coordinate insulin-independent mechanisms to
reduce glucose production [86–92]. Insulin-independent mechanisms are responsible for
about 50% of glucose disposal [88]. Especially important evidence comes from
experiments where insulin or glucose were injected into the hypothalamus and resulted in
decreased peripheral glucose levels and increased insulin sensitivity

[10,11].

Furthermore, deletion of insulin or leptin receptors in hypothalamus results in glucose
intolerance and insulin resistance [14,93].
The brainstem dorsal vagal complex (DVC) is the main neuronal center
responsible for parasympathetic visceral regulation and includes the nucleus tractus
solitarius (NTS), dorsal motor nucleus of the vagus (DMV), and area postrema (Fig 1.2).
Within the DVC, the NTS receives viscero-sensory information, integrates the information
with signals from other brain areas, and projects to preganglionic parasympathetic motor
neurons in the DMV to control visceral functions [94,95]. Previous members of Smith Lab
have shown that the DVC plays a key role in regulating peripheral glucose concentration,
as injection of fibroblast growth factor 19 (FGF19) into the DVC of hyperglycemic mice
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significantly lowers blood glucose levels while increasing the activity of GABAergic
neurons in normoglycemic mice significantly increases peripheral glucose metabolism
[15,96,97]. It is unknown how the alteration of GABAergic neurons in hyperglycemia
affects the peripheral blood glucose levels, which is the body of work presented in Chapter
3.

Figure 1.2 Schematic of dorsal vagal complex’s (DVC) key regulatory position.
The NTS receives visceral afferent input and then projects both glutamatergic (+) and
GABAergic (-) interneurons to the DMV, regulating vagal motor output to viscera. In
addition, NTS is reciprocally connected with several autonomic regulatory centers.
10

1.6

Metabolomics and Metabolome
Metabolism plays a central role in health and diseases. Understanding how

disturbances in metabolism affect disease progression and outcome is vital as new drugs
and strategies are developed. Metabolomics is defined as a large-scale study of small
molecules called metabolites, while the interactions of metabolites are defined as
metabolomes. The state of the cell or organism can be deduced from metabolomic studies
as they show the biochemical activity of the cell/tissue or organism studied. The
metabolome includes amino acids, fatty acids, carbohydrates, vitamins, lipids, and other
molecules and is constantly changing because of a multitude of reactions occurring
[98,99]. Gas chromatography-mass spectrometry (GCMS), liquid chromatography-mass
spectrometry (LCMS), or nuclear magnetic resonance spectroscopy (NMR) techniques
are used to study the metabolome [100]. Two main approaches in the study of
metabolomics are employed: targeted or untargeted metabolomics, the main differences
are summarized in the table below (adapted from Sas et al.) [100–102].
Table 1.1 Comparison of targeted and untargeted metabolomics approaches
Feature

Targeted

Untargeted

Number of
metabolites
detected

Specific subset
(less than 25/run)

Typically about 500
reproducible known
compounds

Identification

Individual
standards

Library and
software based

Quantitative

Yes

No

Data Analysis time

Minimal (n =
10/group and 20
analytes takes 2-3
days)

Significant
(n=10/group takes
4-6 weeks)
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1.6.1

Metabolomics and diabetes
T1DM and T2DM plasma and urine levels have been extensively studied using

metabolomics techniques [42,70,101–106], but regional brain metabolomics during
hyperglycemia is mainly unknown. Arguably the most notable discovery is the
identification of amino acids as predictors of diabetes. Elevated levels of branched chain
amino acids such isoleucine, leucine and valine, were able to predict risk up to 12 years
prior to onset of diabetes [107]. Metabolomics has also been extensively used to study
secondary effects of diabetes such as nephropathy, chronic kidney disease and
atherosclerosis [101].
1.6.2

Stable Isotopic Tracing
Understanding the metabolite abundance does not paint a whole picture and is

insufficient in understanding the effects a disease has on the cell or tissue. Therefore,
measurement of not only metabolite abundance but also the change of abundance over
time, or metabolic flux, is necessary to understand the changes in metabolome [108].
Isotopic tracing is a powerful tool as it can detect relative pathway and nutrient
contributions, in addition to the changes in the flux of metabolites [109]. Changes in
metabolic flux can be the result of a change in production (biosynthesis/anabolism) or a
change in consumption (degradation/catabolism). However, flux cannot be measured by
simply utilizing the mass spectrometer. The assessment of metabolic flux requires nonradioactive stable isotope tracers [110]. Stable isotopic tracing is achieved by giving
animals labeled metabolite, for example
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C6 glucose, and detecting the incorporation of

heavy isotopes into specific metabolites [111,112]. The mass shift due to the heavy
isotope is detected using GCMS or LCMS (Figure 1.3). Data are corrected for the natural
abundance of heavy isotopes, and then presented as fractional enrichment. Stable
isotopic tracing has been used in cell culture, animal models and humans [101].
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Figure 1.3 Detection of labeled metabolite using GCMS or LCMS.
Labeled metabolite lactate has detectable variation in neutron count and mass. m/z of
unlabeled 12C lactate is 219, and fully labeled
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C3 lactate is 222.

Patterns of enrichment of labeled carbons in stable isotopic tracing can be used to assess
the enzymes pyruvate carboxylase and pyruvate dehydrogenase based on isotopologues
enrichment percentage. For example M+2 label of TCA cycle intermediates is used to
analyze pyruvate dehydrogenase while M+3 is used to analyze pyruvate carboxylase
(Figure 1.4).
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Figure 1.4 Analysis of pyruvate dehydrogenase and pyruvate carboxylase using
stable isotopic tracing.
Fully labeled glucose, after turning into pyruvate, has two main entryways into TCA cycle;
pyruvate dehydrogenase (M+2) and pyruvate carboxylase (M+3).

1.7

Overall goals of the dissertation
There are three main goals of the dissertation, 1) to define DVC’s role in whole-

body glucose regulation during hyperglycemia, 2) to develop and implement a protocol for
studying the brain metabolome by utilizing high power focused microwave fixation, and 3)
to understand the effects of hyperglycemia on central carbon metabolism within different
brain regions as well as peripheral organs.
In Chapter 2, we present a STAR protocol developed for studying the brain
metabolome utilizing high power focused microwave fixation. In Chapter 3 we establish a
14

central role for the DVC in peripheral glucose homeostasis, mediated through the
parasympathetic nervous system. In Chapter 4 we investigate hyperglycemia effects on
central carbon metabolism in the neocortex, hippocampus, and DVC given that glucose is
the main source for de novo production of neurotransmitters glutamate and GABA, whose
signaling is altered during T1DM. In chapter 5, we summarize the results presented and
discuss its implication and importance.
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CHAPTER 2. HIGH-POWERED FOCUSED MICROWAVE FIXATION TO STUDY
BRAIN METABOLOME
2.1

Preface
The following Chapter describes a STAR protocol prepared for publication (Parts

2.5-2.8) and methods verification results that is a part of separate publication. The
development of the STAR protocol was designed by Jelena Anna Juras, Lyndsay Young
and Ramon Sun. The manuscript was written and edited by Jelena Anna Juras, Lyndsay
Young and Ramon Sun. Jelena Anna Juras and Lyndsay Young contributed equally to the
STAR protocol, as every part of it was done together. Data in 2.2-2.4 was used in a
separate manuscript prepared for publication. For a detailed description of this
manuscript’s author contribution see Chapter 4.1. For materials and methods see Chapter
4.3.
To make the chapter flow better, the full STAR protocol as prepared for publication
is at the end of the chapter.
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2.2

Introduction
The best techniques to accurately capture physiological brain metabolism in

rodents in vivo rely on nuclear magnetic resonance (NMR) [113–115], wherein mice are
anesthetized, and live animals are used to study metabolic parameters. Metabolites
captured by in vivo NMR are limited, thus large-scale metabolomics studies of the brain
require rapid dissection of brain regions post-mortem followed by cryopreservation and
mass spectrometry detection of metabolites [116–118]. Post-mortem surgical removal of
the brain ranges from 90 seconds to several minutes depending on the individual
performing the resection. It is well documented that metabolism changes postmortem
[119,120] and the rates of metabolic flux through glycolysis and the TCA cycle occur in
seconds [121–123]. Furthermore, artificial tissue hypoxia has been reported in mice
following cervical dislocation [124], decapitation [125], and CO2 euthanasia [126]. Brain
tissue collection through conventional routes results in glycogen degradation and changes
in global protein phosphorylation status [127,128]. A deeper understanding of neuronal
function hinges on expanded metabolic pathway coverage, creating a critical need to
establish an accurate baseline brain metabolome that excludes residual non-physiological
metabolism that occurs during post-mortem brain resection.
Microwave fixation of mammalian tissues use the vibration of water molecules to
produce heat [129], resulting in heat-inactivated protein denaturation and, in principle,
stopping all metabolic processes [130]. Indeed, microwave fixation is frequently used in
pathology laboratories to preserve mammalian tissues for histopathological analyses
[131]. For direct in situ tissue fixation of whole animals, a focused microwave system has
been developed for the rapid inactivation of brain proteins and shown to preserve global
protein phosphorylation through enzyme inactivation, however, they did not look at the
metabolome of brain regions [128]. Similarly, our model places the mouse in a holder and
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in the microwave in a way where the focused beam targets the brain, more specifically
bregma (A-P 0). The peripheral organs are not in the direct path of the radiation beam.
We hypothesize that enzymatic inactivation through microwave fixation would preserve
the brain metabolome. Herein, we compared in situ microwave fixation (0.6 seconds) to
the conventional decapitation, rapid dissection, and cryo-preservation of wild-type C57Bl/6
brain tissues, where enzyme inactivation takes about 90 seconds. We observed a drastic
degradation of free glucose and glycogen for lactate production during the 90 seconds of
enzyme inactivation (traditional cryo-preservation tissue harvesting), which was not seen
with focused microwave where enzyme inactivation took 0.6 seconds.

2.3
2.3.1

Results
In situ microwave fixation preserves brain metabolome
Cellular metabolism continues post-mortem for rodents, with signs of hypoxia

driven metabolic reprogramming [120]. This metabolic reprogramming is especially true
for the brain and capturing an accurate snapshot of the brain metabolome remains a
critical challenge in the field. In this study, we utilized the high-powered focused
microwave specifically designed for the rapid fixation of rodent brain tissue to prevent
postmortem metabolic changes during brain resection. To test the application of
microwave fixation, we designed an experiment to compare the impact of decapitation,
followed by rapid dissection of the brain and cryo-preservation by LN2 where enzyme
inactivation took around 90 seconds (n=3), to the microwave fixation, where enzyme
inactivation took about 0.6 seconds (n=3), (Fig. 2.1A). Brain and other tissues from both
cohorts of animals were cryomilled and prepared for pooled metabolomics analysis by gas
chromatography mass spectrometry (GCMS) for both polar metabolites and biomass
[132–134]. For this study, instead of doing a whole brain analysis, we dissected the brain
into regions, neocortex, hippocampus, and the dorsal vagal complex (DVC), which can be
18

reliably separated during the brain dissection. GCMS metabolomics analyses between 90
seconds and 0.6 seconds needed for enzyme inactivation displayed clear separation by
Partial Least Squares-Discriminant Analysis (PLS-DA) (Fig. 2.1B), and metabolic pathway
enrichment analysis identified glycolysis, gluconeogenesis, TCA cycle, and amino acid in
all three brain regions as key pathways differing between two enzyme inactivation times
(Fig 2.1C). Targeted metabolite analysis of the central carbon pathway revealed a
significant increase in glycogen, glucose, citrate, and a significant decrease in lactate,
malate, and fumarate with HPFM (Fig 2.1D). Since the microwave beam does not have
peripheral organs in its path, we included GCMS analysis of the lung, liver, and muscle as
controls. We only observed changes in glucose and glucose-6-phosphate in liver and the
muscle, but not other metabolites (Figure 2.2). Further, microwave fixation shows
improved variance within groups showing reduced coefficient of variance (CoV) among
multiple metabolites (Fig. 2.1E), indicating that focused microwave with 0.6 seconds time
interval to inactivate enzymes is an improved method over traditional decapitation with
cryo-preservation where enzyme inactivation takes around 90 seconds.
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Figure 2.1 In situ high-power focused microwave fixation (HPFM) preserves brain
metabolome.
(A) Schematic of the experimental design. 6-week-old mice were fasted for 3 hours, and
euthanized by decapitation (top) or microwave fixation (bottom). Brain regions were then
dissected, flash-frozen, and analyzed by GCMS. (B) Partial Least Squares-Discriminant
Analysis (PLS-DA) of neocortex (CTX), dorsal vagal complex (DVC), and hippocampus
(HIPP) metabolites showing distinct separation between 90 seconds and 0.6 seconds
enzyme inactivation. (C) Pathway analysis comparing 90 seconds and 0.6 seconds
enzyme inactivation (performed by Metaboanalyst) in CTX, DVC, and HIPP brain regions.
(D) Representatives metabolite levels from glycogen metabolism, glycolysis, and TCA
cycle between 90 seconds and 0.6 seconds. Values are presented as mean  SEM (n=3
biological replicates), *p<0.05, **p<0.01, ***p<0.001, #p<0.0001, analyzed by student ttest. (E) Coefficient of variance (CoV) analysis of representative metabolites in B. G6P:
glucose 6-phosphate, F6P: fructose 6-phospahte, AMP: adenosine phosphate, Thr:
Threonine, Ser: Serine, Val: Valine, Pro: Proline.

21

Figure 2.2. In situ high power focused microwave fixation (HPFM) to study
metabolome in peripheral organs.
(A) Schematic of the HPFM showing the energy beam hitting the brain but not peripheral
organs. (B) Representative metabolite levels from glycogen metabolism, glycolysis, and
TCA cycle between 90 seconds and 0.6 seconds enzyme inactivation. Values are
presented as mean  SEM (n=3 biological replicates), *p<0.05, **p<0.01, ***p<0.001,
analyzed by student t-test. G6P: glucose 6-phosphate.
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2.3.2

In situ microwave fixation is compatible with stable isotope tracing
Stable isotopic tracing is invaluable for delineating substrate metabolism and

interrogating enzymatic activities [135,136]. To test whether focused microwave fixation is
compatible with stable isotope tracing, we performed oral gavage delivery of
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C-glucose

using a method previously described [133] and performed 0.6 seconds and 90 seconds
enzyme inactivation methods to interrogate isotopic enrichment of central carbon
metabolites between the two different brain fixative strategies (n=3) (Fig 2.3A). We
identified significantly increased enrichment of 13C in glycogen and glycolytic metabolites,
including glucose, DHAP, and PEP in the neocortex between 0.6 seconds and 90 seconds
of enzyme inactivation strategies (Fig 2.3B-C). However, lactate, citrate, fumarate, malate,
and amino acids such as glutamate, glutamine, serine, and GABA were not different
between 0.6 and 90 seconds (Fig. 2.3C). It is likely that even though total pooled
metabolites were changed during 90 seconds of inactivation, both 13C-enriched and 12C in
TCA cycle and amino acid metabolism were either consumed or synthesized at the same
rate during 90 seconds fixation interval, as compared to 0.6 seconds enzyme inactivation
interval. Similarly, we did not observe major changes in
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C-enrichment between 90

seconds and 0.6 seconds enzyme inactivation periods in the lung, liver, and SKM (Fig.
2.4). Collectively, these data suggest 1) glycogen and glucose are utilized to supply
glycolysis during the 90 seconds of tissue resection (Fig. 2.3D), and 2) stable isotope
tracing could be a better strategy then untargeted metabolomics to study brain metabolism
when the focused microwave is not available to prevent conclusions made on data that is
not physiologically relevant.
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Figure 2.3 In situ high power focused microwave fixation (HPFM) is compatible
with stable isotope labeling.
(A) Schematic of the experimental design. In a parallel experiment, as shown in Figure
2.3A, 6-week-old mice were fasted for 3 hours, gavaged with
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C6-glucose, and

euthanized by decapitation (top) or microwave fixation (bottom), brain regions were then
dissected, flash-frozen, and analyzed by GCMS. (B) Schematic showing the stable
isotope tracing glucose in glycolysis and TCA cycle and subsequent interpretations. (C)
Representative isotopologue for M6 of glycogen, glucose, and G6P, M2 of citrate,
fumarate, malate, glutamate, glutamine, GABA, aspartate, and serine, M3 of DHAP, 3PG,
PEP, pyruvate, lactate, citrate, fumarate, malate, glutamate, glutamine, GABA, aspartate
and serine within the prefrontal cortex regions of mice subjected to enzyme inactivation at
90 seconds and 0.6 seconds. Values are presented as mean  SEM (n=3 biological
replicates), *p<0.05, **p<0.01, ***p<0.001, #p<0.0001, analyzed by student t-test. (D)
Model of changes in glucose utilization within cortex between enzyme inactivation at 90
seconds or 0.6 seconds. Bolded red arrows represent overutilized pathways during 09
seconds enzyme inactivation. G6P: glucose 6-phosphate, DHAP: dihydroxyacetone
phosphate, 3PG:3-phosphoglyceric acid, PEP: phosphoenolpyruvate, CTX: neocortex.
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Figure 2.4 13C6 glucose isotope tracing does not alter in the lung, liver, or skeletal
muscle (SKM) with high power focused microwave fixation (HPFM).
Representative isotopologue for M6 of glycogen, glucose, and G6P, M2 of citrate,
fumarate, malate, glutamate, aspartate, and serine, M3 of DHAP, 3PG, PEP, lactate,
citrate, fumarate, malate, glutamate, aspartate and serine between mice subjected to 90
seconds or 0.6 seconds enzyme inactivation. Values are presented as mean  SEM (n=3
biological replicates), *p<0.05, **p<0.01, analyzed by student t-test.
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2.4

Discussion
There is a major scientific interest in deepening our understanding of the brain

metabolome [137,138], as many speculate it will aid in our understanding of brain
physiology and could be key to understanding neurological disease pathology. Brain
metabolism is a highly heterogeneous and rapid cycling series of events; therefore
capturing an accurate snapshot of the brain metabolome is technologically challenging. In
this study, we employed a focused microwave to create a snapshot of the brain
metabolome through in situ heat inactivation and fixation of metabolic enzymes. By
comparing focused microwave, which takes 0.6 seconds and conventional decapitation
with cryopreservation which takes around 90 seconds to preserve metabolites, we found
that focused microwave significantly retained total pools of glycogen, glucose, and citrate,
but decreased levels of lactate, malate, and succinate as compared decapitation with cryopreservation. Our study highlighted the importance of capturing the accurate brain
metabolome and supports the use of a focused microwave to study brain metabolism.
When a focused microwave is not available, data interpretation should be carefully
examined with the assumption that non-physiological metabolism occurs during
cryopreservation. The effect of non-physiological metabolism is the most extensive for
glucose, glycogen, and lactate.
Currently, strategies to study brain metabolism include total pooled metabolomics
analyses for large-scale pathway coverage [116] and, in certain cases, stable isotope
tracing to study metabolic flux or enzyme activity [114,139]. We observed a number of
interesting changes between enzyme inactivation at 0.6 seconds (focused microwave)
and 90 seconds (cryo-preservation) in total pooled metabolomics analysis. Primarily,
fixation of brain with focused microwave resulted in significantly increased levels of
glycogen, glucose, citrate, aKG compared to cryo-preservation. In addition, microwave
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fixation resulted in a significant decrease in lactate, succinate, and malate as compared
to cryo-preservation. These data suggest increased utilization of glycogen and glucose for
glycolysis and lactate production during the 90 seconds interval to preserve metabolites.
Interestingly, the metabolic shift toward lactate production is often observed during
hypoxia [140] and occurs frequently during cancer metabolism [141]. One possible
explanation of this metabolic phenotype is that after euthanasia, the lack of circulation
supplying the brain creates a hypoxic environment for the metabolically active brain cells,
resulting in a shift towards a hypoxic metabolic phenotype. It is worth noting we did not
observe a change in amino acid abundances between the two time intervals of fixation
(0.6 seconds and 90 seconds). Amino acids such as glutamate, glutamine, aspartate, or
GABA were comparable between the two different brain harvest strategies. Our GCMS
settings includes heating the column to a maximum temperature of 280C, allowing us
only to study heat resistant metabolites. In addition, if microwaving produced heat related
artifacts, due to high temperature of the column, the artifacts would not make it to the
detector.
Stable isotope tracing is a powerful technique to study metabolic flux and enzyme
activity in vivo and is frequently used to study brain metabolism [114,139]. We performed
isotopic tracing experiment using an in vivo oral delivery method developed previously
[133] to test the effects of in situ fixation by focused microwave on stable isotope
enrichment of central carbon metabolites. In line with pooled metabolomics analysis, 90
seconds of enzyme inactivation as compared to 0.6 seconds resulted in a significant
increase in glucose and glycogen utilization, as demonstrated by decrease in the
enrichment of M6 isotopologue of glucose and glycogen, and an increase in enrichment
of M3 isotopologue of 3-PG. To our surprise, we did not observe major changes between
0.6 seconds and 90 seconds intervals in isotopic enrichment of TCA cycle metabolites.
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M2 and M3 isotopologues of citrate, fumarate, and malate were consistent between the
two time intervals. These data imply that although the total pool of metabolites was
changing during 90 seconds of cryo-preservation, it did not affect the isotopic ratios or
enrichment. Further, both labeled and unlabeled
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C fractions were either produced or

consumed at the same rate. Based on these data, we recommend the use of stable
isotope tracing to study brain metabolism when focused microwave is not available.
The method development presented here is the first step of creating an accurate
snapshot of the brain metabolome without influence from post-mortem brain resection.
We would like to highlight that rodent brain metabolism is highly sensitive to stimuli such
as handling and stress [142], anesthesia [143], and time post-euthanasia [120]. Additional
steps will be needed to control these factors in the future to truly capture the brain
metabolome. Future studies should focus on isolating single cell types through fluoresceactivated cell sorting (FACS) or magnetic separation methodologies post focused
microwave to define the cell type specific brain metabolism in healthy and diseased tissue.
It would also be of interest to test whether focused microwave is compatible with new
single-cell technologies such as matrix-assisted laser desorption ionization MALDI mass
spectrometry imaging [144], single cell RNAseq [145], and spatial proteomics analyses
[146,147].
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2.5

Summary
Metabolism does not stop immediately postmortem, when rodents are decapitated.

Rather it undergoes substantive change induced by post-mortem dissection and the onset
of hypoxia, thus presenting a challenge to capture physiological changes in the
metabolism induced by disease. Enzymes can be stopped almost instantaneously by
denaturation, therefore we employed high-power focused microwave (HPFM) fixation to
stop all metabolic changes in 0.6 seconds. This workflow details the step-by-step highpower focused microwave fixation protocol for the untargeted and stable isotopic tracing
metabolome study in various tissues.

2.6

Graphical Abstract

Figure 2.5 Graphical abstract of the protocol.
In short, mice were placed in a mouse holder, secured with silicon rods, and placed in the
microwave apparatus. The microwave was run at 5.00 kW for 0.6sec. Utilizing the high30

power microwave results in euthanasia of animals and tissue fixation. Regions of the brain
as well as peripheral organs were then dissected. We employed GCMS and HPLC-QTOF
to analyze the metabolome.

2.7

Preparation of the high-powered focused microwave
Microwave Specifications - For proper microwave fixation, machine outlets will

need to be configured to meet power requirements of 190-240V 3-A 3 Phase or 380-440V
20A 3 Phase prior to operation.
Timing: 30 min
The microwave has a warm-up time before use. Turn the microwave (Figure 2.6.)
on and leave it for 30 minutes. Set the power of the microwave to 5kW and time to 0.65
seconds.

Figure 2.6 Muromachi Kikai Company High Power Focused Microwave.
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2.7.1

Preparation of animal holder
Choose the appropriate size of the animal holder (Figure 2.7). Fill the animal holder

with DI water carefully, ensuring that no bubbles are trapped in the holder. This is
extremely important as the water is used to dissipate the heat during the fixation process.
Water must be replaced after each animal.

Figure 2.7 Animal holder for HPFM
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2.7.2

Key Resources Table

Table 2.1 Key resources needed to run high power focused microwave

REAGENT or RESOURCE
SOURCE
Chemicals, Peptides, and Recombinant Proteins
Ethanol
Decon Labs
Other
Muromachi
High power-focused microwave
Kikai Company

Animal Holder, TAW-174P

Muromachi
Kikai Company

60 mL syringe only, luer lock tip
Over the head ear muffs
Safety Glasses
N95 mask

BD Sciences
Fisher Scientific
Fisher Scientific
Fisher Scientific

2.7.3

IDENTIFIER
CAS#: 64-17-5
MMW-05
WJM-24 for
15-20g
Mouse,
WJM-28 for
20-40g
Mouse,
WJM-30 for
40-50g Mouse
BD 309653
19-130-1978
19-181-514
18-999-473

Step-by-step method details

2.7.3.1 Placing the animal into the holder
Timing: 1 min
The animal must be secured in the holder properly.
Restrain the animal
Guide the animal’s snout into the animal holder
Secure the animal in the apparatus with the holder plunger. Make sure the animal
is not too tight or too loose.
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2.7.3.2 Place the animal into the high-power focused microwave
Timing: 1 min
Placement of the animal holder within the microwave is crucially important for
proper fixation. Misplacement will result in under or over fixation of the tissue of interest.
Following the markings on the interior of the microwave, place the animal holder
inside of the microwave (Figure 2.8).
Close the metal door on the microwave.
Run the microwave.
Carefully remove the animal from the holder.
Caution: Both animal and the holder are hot after exposure to microwave. Leave
the animal to sit on RT for 4 min before dissection.

Figure 2.8. Placement of animal holder in high-power focused microwave
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2.7.3.3 Microwave re-charging
Timing: 2 min
The microwave needs 2 min between the animals in order to recharge to the
appropriate power.
For consistency between animals, we found 10 min was sufficient for fixation of all
(n=3) animals in the studies.
2.7.3.4 Cleaning the animal holder between animals
Timing: 2 min
The animal holder must be cleaned and prepared for next animal.
Cleaning should be done by using 70% Ethanol, spraying, and wiping down the
animal holder.
Replace the current water in the animal holder with fresh DI water.

2.8

Expected outcomes
In our experimental protocol, we describe a detailed method for preserving

metabolites in the brain and other tissues. Post-extraction tissue was run on GCMS and
LCMS. Other groups have reported Western Bloot analysis for protein glycosylation after
microwave fixation [128].
2.8.1

Limitations
The described protocol works well when tissue barriers in an animal are intact. In

other words, animals do not have craniotomy or other major procedures that would
compromise the structural integrity of the tissue and result in overheating or underheating
the tissue.
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2.8.2

Troubleshooting
Problem 1: Tissue is under or over-fixed. Tissue will be in liquid form if under

fixated, or extremely fragile if overfixated.
Potential solution: Animal's weight, genotype, and water content will greatly
influence the quality of the tissue. Before each study, it is necessary to perform
optimization for genotype and body weight.
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CHAPTER 3. SYSTEMIC GLUCOSE REGULATION BY AN INHIBITORY
BRAINSTEM CIRCUIT IN A MOUSE MODEL OF TYPE I DIABETES
3.1

Preface
The following chapter is a part of a manuscript prepared for publication. The

manuscript comprises of two separate sets of experiments: in vivo blood glucose
measurements and electrophysiological experiments. The study design and interpretation
of the results for the in vivo blood glucose measurements were conducted by Jelena Anna
Juras and Bret Smith. Surgery procedures, tissue processing, animal handling, blood
glucose data collection, analysis, and statistics for in vivo blood glucose measurements
were conducted by Jelena Anna Juras. Given that study design and interpretation of
electrophysiological experiments were conducted by Sole Pitra and Bret Smith these data
are not shown in the thesis. Abstract below is the same as in the manuscript to offer a
general understanding of the manuscript. The manuscript was written and edited by
Jelena Anna Juras, Sole Pitra and Bret Smith.

3.2

Abstract
Previous work showed that modulating the electrical activity of inhibitory neurons

of the dorsal vagal complex (DVC) is sufficient to alter whole-body glucose concentration
in normoglycemic mice. Here we tested the hypothesis that deactivating GABAergic
neurons in the dorsal hindbrain of hyperglycemic mice decreases synaptic inhibition of
parasympathetic motor neurons in the dorsal motor nucleus of the vagus (DMV) and
decreases systemic glucose levels. Chemogenetic activation of GABAergic NTS neurons
in normoglycemic mice increased their action potential firing, resulting in increased
inhibitory synaptic input to DMV motor neurons and elevated blood glucose concentration.
Deactivation of GABAergic DVC neurons in normoglycemic mice altered their electrical
activity but did not alter systemic glucose levels. Conversely, stimulation of GABAergic
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DVC neurons in hyperglycemic mice changed their electrical activity but did not alter
whole-body glucose concentration, while deactivation of this inhibitory circuit decreased
circulating glucose concentration. Peripheral administration of a brain impermanent
muscarinic acetylcholine receptor antagonist abolished these effects. This inhibitory
brainstem circuit emerges as a key parasympathetic regulator of whole-body glucose
homeostasis that undergoes functional plasticity in hyperglycemic conditions.

3.3

Introduction
Blood glucose concentration is modulated through peripheral actions of the

hormones insulin and glucagon, which interact with various organ systems to impact
glucose storage, release, and cellular utilization. Relatively recently, insulin-independent
glucose homeostatic mechanisms have been identified [2–7], and the regulatory role of
the brain has gained acceptance [88]. Early investigation focused on hypothalamic nuclei,
into which injection of insulin, glucose, or leptin decreases systemic blood glucose levels
[10,148,149], while deletion of insulin or leptin receptors decreases glucose tolerance and
results in insulin resistance [14,93]. However, there is not a direct connection between the
hypothalamus and viscera. Rather, these effects are mediated largely by connections with
brainstem vagal circuits [3,148,150].
The brainstem dorsal vagal complex (DVC) has been shown to play a role in
glucose and energy homeostasis [15,97,151–155]. The DVC is the main neuronal region
responsible for parasympathetic visceral regulation and includes the nucleus tractus
solitarius (NTS), dorsal motor nucleus of the vagus (DMV), and area postrema (AP).
Within the DVC, the NTS receives viscerosensory vagal afferent information, integrates
the information with signals from other brain areas, and projects to preganglionic
parasympathetic motor neurons in the DMV to control visceral functions. Furthermore, the
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blood-brain barrier in the NTS and AP is permeable due to fenestrated capillaries[156],
and may allow central access to circulating chemicals. Neurons in the DVC, and
particularly the GABAergic NTS neurons, are sensitive to multiple circulating chemicals,
including glucose and metabolic signaling hormones [157–164], making the DVC uniquely
positioned as a potential central omphalos for modulating peripheral glucose metabolism.
Type I diabetes causes a sustained increase in glutamate release and
postsynaptic GABA signaling in the DMV [165–171]. In normoglycemic mice,
chemogenetic, designer receptor exclusively activated by designer drugs (DREADDs)
mediated activation of GABAergic neurons in the dorsal hindbrain results in an insulinindependent increase in blood glucose mediated by the vagus nerve, while deactivation
of the same neuron group has no glucoregulatory effect [97]. Because of the increased
GABA release and receptor function in the DVC of chronically hyperglycemic mice, we
employed a similar approach to investigate how selective activation (or deactivation) of
inhibitory, GABAergic neurons in the dorsal hindbrain modulates whole-body glucose
levels in diabetic mice. We hypothesized that, contrary to what occurs under
normoglycemic conditions, deactivating GABAergic neurons in the DVC of hyperglycemic
mice would disinhibit DMV motor neurons and increase their activity, resulting in
decreased whole-body blood glucose levels.

3.4
3.4.1

Materials and Methods
Animals
All experiments were performed on male and female Vgat-ires-Cre knock-in mice

(Slc32a1tm2(cre)lowl/J, 016962, The Jackson Laboratory, Bar Harbor, ME). Mice were
housed and cared for in the University of Kentucky Division of Laboratory Animal
Resources facilities under normal 14:10 light-dark condition with food (Tekad 2018,
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Envigo, Indianapolis, IN) and water available ad libitum, except where noted and
according to protocols approved by the University of Kentucky Animal Care and Use
Committee.
3.4.2

Stereotaxic DREADDs construct injections
At seven weeks of age (± 3 days), mice were anesthetized using isoflurane (5%

induction, 3% maintenance) and placed on a heating pad in a stereotaxic frame (Kopf
Instruments, Tujunga, CA). The skull was exposed using a midline incision, and an
approximately 1.5 mm craniotomy was made at the following stereotaxic coordinates from
bregma: AP = 7.15 mm, ML = 0.25 mm, DV = 3.30 mm, targeting the NTS region. 150 nl
of floxed DREADDs constructs, pAAV8-hSyn-DIO-hM3D(Gq)-mCherry (plasmid #44361,
Addgene, Cambridge, MA), pAAV8-hSyn-DIO-hM4D(Gi)-mCherry (plasmid #44362,
Addgene), or blank plasmid was injected using a 5 l syringe equipped with a 32 gauge
blunt-tipped needle (Hamilton, Reno, NV) over a period of 10 minutes, at a rate of 15
nl/minute. The needle was kept in place for 10 minutes before withdrawing. Mice were
allowed to recover for 72 h following surgery and then were acclimated to handling for 3
weeks. Acclimation included daily handling, changing the home cage, puncture of lateral
tail vein, and intraperitoneal (i.p.) injection of 0.1 ml of saline (Figure 3.1).
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Figure 3.1. Experimental design for in vivo experiments.
Seven-week-old male and female mice were injected with either Gi or Gq virus. After
recovery, mice were acclimated to handling for 21 days. Blood glucose was then tested
upon administration of CNO or saline, the opposite treatment was administered three days
later. Half the mice then received STZ, resulting in hyperglycemia within approximately 48
h. Mice were hyperglycemic for 14 days and blood glucose was measured again upon
administration of CNO or saline in balanced cohorts. A subset of mice was pre-treated
with methyl-scopolomine to block peripheral muscarinic receptors prior to CNO treatment.
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3.4.3

In vivo glucose assessments
Three weeks after viral delivery, mice were randomly selected to receive either

vehicle (0.9% saline + 0.1% DMSO) or clozapine-N-oxide (CNO, 1 mg/kg). All mice,
across all cohorts started fasting between 8 - 9 am. Mice were fasted for three hours before
receiving an i.p. injection of either vehicle or CNO. Initial lateral tail vein puncture was
performed at the time of fasting and subsequent measures were performed by removing
the scab to allow for free-flowing blood. Blood glucose levels were measured by handheld
glucometer (Nova Max Plus, Nova Biomedical, Waltham, MA). Animals remained fasted
and blood glucose was measured every 30 min for 5 h after injection of vehicle or CNO.
The following day mice were fasted again and a 24 h measurement was taken. Each
animal received the opposite treatment 3 days later to provide a counter-balanced design.
One cohort of normoglycemic mice (n = 6) received 2 injections of CNO 72 hours apart to
verify similar response to repeated CNO application.
Following the 24 h measurement after the second testing, mice were injected with
streptozotocin (STZ, 200 mg/kg, i.p., Sigma-Aldrich, St. Louis, MO) or citric acid (CA, 0.1
M), after a 6 h fast. Mice were monitored daily for weight and blood glucose levels. Mice
with blood glucose concentration  300mg/dL were considered hyperglycemic. After at
least 14 days (14-16 days) of hyperglycemia, mice were tested again with CNO and
vehicle, as above. One cohort of diabetic mice (n = 6) received a third CNO test after being
pre-treated with methylscopolamine (MSA, 1 mg/kg, i.p.) 30 min prior to CNO injection,
and blood glucose was measured for 5 h and at 24 h post-CNO injection. A separate
cohort of normoglycemic mice that did not receive DREADDs viral constructs was tested
for potential off-target or systemic effects of CNO or its metabolite, clozapine at 1 mg/kg
and 10 mg/kg [172]. Data are expressed as the change in blood glucose measured
immediately prior to injection (t = 0).
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To verify DREADDs construct location, mice were anesthetized with isoflurane
inhalation to effect and perfused transcardially with heparinized saline (10 units/mL),
followed by 4% paraformaldehyde (PFA) in 0.1 M phosphate-buffered saline (PBS). The
brain was removed and postfixed for 1 h in 4% PFA. The brainstem was then blocked at
the rostral edge of the cerebellum and immersed in 30% sucrose in 0.1 M PBS overnight
until equilibration. Sections were cut at 30 µm on a cryostat, mounted on slides, visualized
with epifluorescence optics (Olympus BX40, Center Valley, PA), and imaged using a
SPOT RT camera (Diagnostic Instruments, Sterling Heights, MI).
3.4.4

Data Analysis
In vivo glucose measurements are reported as mean  standard error of the mean

(SEM). Repeated-measures ANOVA with Tukey’s post hoc was used to determine if CNO
injection significantly changed blood glucose concentration. Animals in which mCherry
was expressed in the NTS (i.e., indicating DREADDs transfection) were used in the
analysis, blood glucose did not change in mice in which the NTS exhibited no mCherry
labeling (n = 11) or when the label was identified mainly outside the DVC (i.e., off-target
injections, n = 5), and these mice were not further analyzed. Animals in which blank
plasmid was injected (n = 5) showed no blood glucose change. Unless otherwise stated,
statistical significance for all measures was set at p < 0.05.

3.5

Results
The present study involved in vivo chemogenetic modulation of cre-recombinase-

expressing GABAergic neurons in the dorsal hindbrain, centered on the caudal NTS.
Stereotaxic injection of cre-recombinase-inducible adeno-associated viruses expressing
the DREADDs with mCherry as the fluorescent marker allowed the activation or inhibition
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of this neuronal population to study circulating glucose levels under normal physiological
conditions and in a model of type 1 diabetes.
3.5.1

Chemogenetic activation of GABAergic NTS neurons
To assess the effects of GABAergic activation on whole-body glucose levels,

normoglycemic mice were subjected to CNO (1 mg/kg) or vehicle (0.9% saline and + 0.1%
DMSO) 3 weeks after viral inoculation with the excitatory hM3D(Gq) DREADDs construct.
There was no difference in baseline blood glucose levels before receiving saline (144 
11 mg/dL) or CNO injection (143  13 mg/dL). As shown in Figure 3.2C, CNO injection in
normoglycemic mice (n = 10) resulted in an elevation of blood glucose concentration within
15 min, which was significantly different than after vehicle injection by 30 minutes (p<0.05),
and continued to be significantly elevated 2 hours post-injection. The response to CNO
was not different between mice that received CNO as a first or second injection,
preliminary studies in six mice transfected with excitatory hM3D(Gq) DREADDs showed
no decrement in response with repeated CNO treatments at three-day intervals (not
shown).
A subset of the same mice was then subjected to a single injection of STZ (200
mg/kg) and maintained in a hyperglycemic state for 14 days before either vehicle or CNO
injection. There was no difference in baseline blood glucose level before receiving saline
(403  53 mg/dL) or CNO injection (397  37 mg/dL, p>0.05). Activation of dorsal hindbrain
GABA neurons with CNO injection in hyperglycemic mice (n = 7) had no effect on blood
glucose levels at any time point after injection (p>0.05, Fig 3.2D).

Thus, whereas

excitatory DREADDs activation in GABAergic neurons of the dorsal hindbrain led to
increased blood glucose concentration in normoglycemic mice, activating the same
neurons after two weeks of hyperglycemia had no effect on blood glucose.
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Figure 3.2. Chemogenetic activation of GABAergic neurons of the NTS increases
whole-body glucose levels in normoglycemic but not hyperglycemic mice.
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A, Schematic representation of the location of stereotaxic microinjection of pAAV-hSynDIO-hM3D(Gq) into the dorsal vagal complex. B, Representative image of DREADDs
expression 6 weeks after inoculation. C, Blood glucose contraction after i.p. administration
of CNO (1 mg/kg) or vehicle (0.9% saline + 0.5% DMSO) in normoglycemic mice (n = 10).
D, Blood glucose contraction after i.p. administration of CNO (1 mg/kg) or vehicle (0.9%
saline + 0.1% DMSO) in hyperglycemic mice (n = 7). Bars, SEM, * p < 0.05, ** p < 0.01.
AP – area postrema, CC – central canal.
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3.5.2

Chemogenetic inhibition of GABAergic NTS neruons.
To evaluate the effects of inhibiting GABAergic neurons in the dorsal hindbrain on

blood glucose levels, normoglycemic mice were subjected to CNO (1 mg/kg) or vehicle
(0.9% saline and + 0.5% DMSO) 3 weeks after viral inoculation with the inhibitory
hM4D(Gi) DREADD construct. There was no difference in baseline blood glucose levels
before receiving saline (145  13 mg/dL) or CNO injection (152  7 mg/dL). Similar to
previous results[97], injection of CNO in normoglycemic mice resulted in no change in
blood glucose concentration (n = 6, Fig. 3.3).
The same mice were then subjected to a single injection of STZ (200 mg/kg) and
maintained in a hyperglycemic state for 14 days. Injecting CNO in hyperglycemic mice
resulted in a significant decrease in blood glucose concentration starting 30 min postinjection (p<0.05) and continuing for 2.5 hours (n = 6). Pre-treatment of 6 mice with
methylscopolamine (MSA, 1 mg/kg) 30 minutes before administration of CNO prevented
the effect of DREADDs mediated inhibition of GABAergic dorsal hindbrain neurons on
blood glucose concentration (p>0.05, Fig 3.3). There was no difference in baseline blood
glucose levels before receiving saline (417  29 mg/dL), CNO (442  32 mg/dL) or
methylscopolamine injection (433  21 mg/dL).
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Figure 3.3. Chemogenetic deactivation of GABAergic neurons of the NTS
decreases whole-body glucose levels in hyperglycemic, but not normoglycemic
mice.
A, Blood glucose contraction after i.p. administration of CNO (1 mg/kg), vehicle (0.9%
saline + 0.5% DMSO) in normoglycemic mice (n = 6). B, Blood glucose contraction after
i.p. administration of CNO (1 mg/kg), vehicle (0.9% saline + 0.5% DMSO) or
methylscopolamine (MSA, 1 mg/kg) in hyperglycemic mice (n = 6). Bars, SEM, * p < 0.05,
** p < 0.01.
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3.6

Discussion
The concept of brain-centered whole-body glucose regulation has been gaining

appreciation over the past two decades, but the role of the parasympathetic nervous
system in regulating systemic blood glucose levels remains unclear, especially after
periods of sustained diabetic hyperglycemia. Synaptic and extra-synaptic GABAergic
inhibition has been shown to be a key modulator of parasympathetic drive to
subdiaphragmatic viscera [159,173–175], and both synaptic and extra-synaptic GABA
signaling in DMV neurons is upregulated in hyperglycemic mice [166,167]. Therefore, we
investigated how GABAergic neurons within the dorsal hindbrain contribute to systemic
blood glucose regulation after several days of hyperglycemia. In this study, we utilized
DREADDs constructs to selectively activate or deactivate GABAergic neurons in the
dorsal hindbrain, particularly the NTS, in both normoglycemic and hyperglycemic mice and
measured whole-body glucose levels. As previously described our results confirmed that
remote chemogenetic activation of GABAergic NTS neurons in normoglycemic mice is
sufficient to increase blood glucose concentration, while deactivation of these neurons
failed to alter blood glucose levels [97]. Conversely, deactivation of GABAergic hindbrain
neurons resulted in a decrease in blood glucose levels in hyperglycemic mice. The CNOdriven decrease in blood glucose concentration was abolished upon administration of
methylscopolamine, a muscarinic acetylcholine receptor antagonist that does not access
the brain, consistent with a vagally mediated change in peripheral glucose metabolism.
Neurons in the DVC are capable of glucosensing [176–178], and changes in
nutrient concentration can lead to modification of DVC circuitry, including sustained
changes in synaptic and intrinsic neuronal properties that affect the function of the system
[162,167,171,179,180]. Activation of excitatory DREADDs in GABAergic NTS neurons
produced a significant change in blood glucose levels mediated by the vagus nerve and
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produced through an increase in glucagon release and hepatic gluconeogenesis [97].
Even though cellular and synaptic effects of inhibitory DREADDs in the DVC were evident,
systemic effects in terms of altered glucose levels were not detected[97]. These findings,
which were replicated here (electrophysiological data not shown), suggest that
disinhibition of DMV motor activity alone is not sufficient to induce hypoglycemia normally.
However, since the effect of GABA release in the DMV is upregulated after periods of
sustained hyperglycemia due to increased tonic GABA current density [165,167], and
increased inhibition of DMV neurons tends to increase blood glucose concentration
[91,181], we hypothesized that suppression of inhibition in hyperglycemic mice would have
a greater systemic effect than in normoglycemic mice. There was no glycemia related
difference in the effect of CNO on action potentials in GABAergic NTS neurons or on
synaptic currents in downstream DMV neurons (electrophysiological data not shown).
After sustained hyperglycemia, however, tonic GABA currents mediated by extrasynaptic
receptors are upregulated in the DMV[166], implying a greater effect of reduced GABA
release in DMV motor neurons from hyperglycemic mice. The specific contribution of tonic
GABA currents in DMV neurons in regulating blood glucose remains to be clarified.
Alternatively, the elevated glucose levels in STZ-treated mice could result in a ceiling
effect due to the already elevated glucose and saturation of downstream visceral
mediators of glucose regulation. This is consistent with the finding that DREADDsmediated excitation of DMV motor neurons blunted the peak response during a glucose
tolerance test [181].
To address concerns that the DREADDs system causes off-target effects [172],
several control experiments were performed. Blood glucose concentration was measured
post-CNO administration in mice that received blank viral construct, mice that received no
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viral construct, mice that had off-target transfection, and mice that had no visible
transfection. There were no effects of CNO injection in any of these control experiments.
Finally, inhibiting GABAergic neurons was sufficient to lower blood glucose levels
in a hyperglycemic model in which insulin is significantly depleted, suggesting that the
response was likely insulin independent. We speculate, based on Boychuck et al. [97],
that these results are due to decreased gluconeogenesis, but the peripheral mechanism
beyond involvement of parasympathetic output remains to be determined. These results
further establish the link between the dorsal hindbrain and systemic glucose metabolism
and highlight the need to continue investigating the role of GABAergic brainstem neurons
in whole-body blood glucose regulation.
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CHAPTER 4. HYPERGLYCEMIA DRIVEN METABOLIC REPROGRAMMING IN THE
BRAIN
4.1

Preface
Parts of the following chapter comprises a manuscript prepared for publication.

The study design and interpretation of the results were conducted by Jelena Anna Juras,
Bret Smith and Ramon Sun. Induction of diabetes, handling of animals, daily
measurement weights/blood glucose concentration, oral gavage of
derivatization

of

samples,

perfusion

of

mice,

slicing

of

tissue,

13

C6 glucose,
free-floating

immunofluorescence, image acquisition and data analysis was done by Jelena Anna
Juras. Madison Webb helped with the development of IF protocols, the development of
image acquisition protocols and the analysis of IF staining. Lyndsay Young helped with
animal euthanasia and GCMS method development. Kia Markussen and Ron Bruntz
helped with developing methods for data analysis and helped with the verification of data.
Michael Bouoncristiani, Kayli Bolton, Peyton Colbrun, Meredith Williams and William
Sanders helped with tissue homogenization, daily blood glucose measurements, and data
input. Chi Wang ran power analysis of GCMS data. The manuscript was written by Jelena
Anna Juras and Ramon Sun, and edited by Jelena Anna Juras, Kia Markussen, Lyndsay
Young, Lindsey Conroy, Tara Hawkinson, Mathew Gentry, Bret Smith and Ramon Sun.
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4.2

Introduction
The brain consumes 20% of circulating glucose [182] and although debated,

neurons are proposed to be the major glucose-consuming cells of the brain [71,183]. The
major energy demand in the brain is for neuronal signaling and cellular processes needed
to support healthy transmission of neuronal signals. Glucose is crucial in many cellular
processes and glucose metabolism of the brain can be subdivided into catabolic or
anabolic processes. Catabolic processes involve the breakdown of glucose for energy
production via glycolysis, the Tricarboxylic acid cycle (TCA) and electron transport chain
[184]. The anabolic processes entail glucose as a building block of many molecules,
including lipids [185], and complex carbohydrates such as glycans [186], chondroitin [187]
and heparin sulfate biopolymers [188], all of which are critical biomass and structural
components of the brain. Furthermore, neurotransmitters such as GABA and glutamate
can be synthesized de novo from glucose carbons [189]. Given that brain glucose
participates in a numerous of metabolic processes from bioenergetics to neurotransmitter
and biomass production, it is difficult to decipher which downstream processes are
perturbed from alterations in availability or concentration of glucose.
Type I diabetes mellitus (T1DM) is a complex metabolic disorder resulting from
autoimmune loss of pancreatic -cells, affecting more than 20 million people worldwide.
Effects of chronically elevated blood glucose are not only seen in peripheral organs but
also in the brain. It has been shown that people with T1DM have decreased mental speed
and flexibility [39,72,73]. Glucose homeostasis is modulated through the actions of two
hormones: insulin and glucagon. In recent years it has been shown that beyond isletcentric glucose regulation, various brain nuclei, most notably in hypothalamus and
brainstem, are involved in insulin-independent glucose homeostasis [2–4,87,148,149].
The dorsal vagal complex (DVC) is a brainstem nucleus that has been shown to participate
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in glucose and energy homeostasis [15,97,151–154]. The DVC is the hub of
parasympathetic visceral regulation as it receives sensory information from the viscera
through afferent vagal branches and can modulate visceral functions through
parasympathetic motor neurons. T1DM results in a sustained increase in glutamate and
glutamate-induced GABA release in the DVC [165,168,169] and, as shown in Chapter 3,
modulation of GABAergic neurons in the DVC alters peripheral glucose concentration via
the parasympathetic nervous system.
Given the importance of glucose as a precursor for various macromolecules, the
central role that the DVC plays in insulin-independent glucose homeostasis and the effects
of hyperglycemia on mental flexibility, we investigated the effects of hyperglycemia on
metabolome and glucose flux in several brain regions: neocortex, hippocampus and DVC,
as well as peripheral organs. We hypothesized that hyperglycemia would lead to glucose
hypometabolism in the brain in the neocortex and hippocampus but not the DVC. Utilizing
untargeted metabolomics we found that glucose concentration was significantly elevated
across all regions but glycogen and glucose-6-phosphate remained unchanged with
hyperglycemia only in DVC. Interestingly pyruvate and lactate were unchanged across all
regions indicating that hyperglycemia does not affect anaerobic cellular respiration.
Intermediates of the tricarboxylic acid (TCA) malate and fumarate are significantly
decreased with hyperglycemia only in DVC, suggesting that hyperglycemia in DVC
preferentially affects TCA cycle. Furthermore, we observed a significant decrease in
glutamate across all regions while glutamine and GABA were unchanged, suggesting
neurotransmitter regulation disturbance. Stable isotopic tracing of uniformly labeled

13
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glucose was employed to assess carbon flux in different brain regions perturbed by T1DM
to understand its effect on glycolysis, tricarboxylic acid cycle, and neurotransmitter
synthesis. We found that hyperglycemia results in metabolic reprogramming with a
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significant decrease in glucose utilization and we demonstrated decrease in
immunofluorescent labeling of GLUT2, a neuronal glucose transporter, as well as
enzymes pyruvate dehydrogenase and pyruvate carboxylase, responsible for anaplerosis
of TCA cycle intermediates, indicating glucose hypometabolism phenotype.

4.3
4.3.1

Materials and Methods
Chemicals and Reagents
HPLC grade methanol (34860-4X4L-R) and methoxyamine hydrochloride

(226904-25G) were purchased from Sigma Aldrich (Burlington, MA, USA). Silylation
Reagents, MSTFA + 1% TMCS Reagent (TS-48915) and pyridine (TS-27530) were
purchased from Thermo Fisher Scientific (Waltham, MA, USA). Amber vials (5184-3554),
blue screw caps (5182-0717) were purchased from Agilent Technologies (Santa Clara,
CA, USA). Streptozotocin (572201) PBS (P3813) , Triton X (X100), Tween 20 (P1379)
were purchased from Sigma-Aldrich (St. Louis MO). Sodium citrate dihydrate (BP327),
Citric acid anhydrous (A940), normal goat serum (31873) and OCT compound (23-730571), 2-methylbutane (019387AP), and ProlongGlass (P36984) were purchased from
Thermo Fisher Scientific. [U-13C] Glucose was obtained from Cambridge Isotope
Laboratories (Tewksbury, MA, USA).
4.3.2

Animals
All experiments were performed on either male Vgat-ires-Cre knock-in mice

(Slc32a1tm2(cre)lowl/J, 016962, The Jackson Laboratory, Bar Harbor, ME) or C57BL6
mice (000664, The Jackson Laboratory). Mice were housed and cared for in the University
of Kentucky Division of Laboratory Animal Resources facilities under normal 14:10 lightdark conditions with food (Tekad 2018, Indianapolis, IN) and water available ad libitum,
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except where noted and accordaning to protocols approved by the University of Kentucky
Animal Care and Use Committee.
4.3.3

Induction of hyperglycemia and in vivo glucose assessment
At 6 weeks of age, mice were injected with streptozotocin (STZ, 200mg/kg, i.p.,

Sigma-Aldrich, St. Louis, MO) in citric acid (CA, 0.1M), after a 6 hour fast. Mice were
monitored daily for weight and blood glucose levels. Blood glucose levels were measured
by handheld glucometer (Nova Max Plus, received from American Diabetes Wholesale,
Pompano Beach, FL), using 0.3L of blood from the tail vein. Nova Max glucose test strips
were used (#8548043523, ADW Diabetes, Pompano Beach, FL). Levels above 300mg/dL
were considered hyperglycemic. Mice were used for experiments after at least 14 days
(14-16 days) of hyperglycemia.
4.3.4

Gavage of [U-13C] glucose
[U-13C] Glucose was dissolved in ddH2O (Millipore Milli-Q, Bedford, MA, USA)

based on the average mouse cohort bodyweight (2 g [U-13C] glucose/kg bodyweight). After
a 3 hour fast, 250 µL of glucose solution was administered via oral gavage. Tissues were
collected at 30 minutes and 2 hours post-gavage. Blood glucose levels were measured
before fasting, at tracer delivery and before microwave was used.
4.3.5

Microwave fixation
Mice were euthanized by microwave fixation at 5kHz for 0.6 seconds (MMW-05,

Muromachi Kikai Company, Japan). Brain regions (hippocampus, neocortex, DVC), as
well as muscle and liver, were dissected postmortem.
4.3.6

Immunofluorescence
Separate cohort of mice were briefly exposed to anesthesia until sedated and

transcardially perfused with Heparin-PBS (10 units/mL), followed by 4% PFA. Tissue was
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post-fixed for 24 hours in 4%PFA and then cryoprotected with 30% sucrose in 0.01M PBS.
The tissue was frozen with isopentanes and cut at 20m with a sliding microtome. Staining
was done free-floating in 24-well plates without inserts. Three sections of the brain and 4
sections of brainstem tissue, serially cut into 8 wells was rinsed with 0.01M PBS, incubated
for 1 hour in 5% normal goat serum in 0.3% Triton X-100 in PBS. The tissue was then
incubated at room temperature in the primary antibody (table 4.1) diluted in 1% normal
goat serum, followed by 3 x 15 minutes rinses in 0.05% Tween-20 in PBS. Tissue was
then incubated for 1 hour in secondary antibody diluted in 1% normal goat serum in PBS.
For multiple labeling, primary antibodies were incubated for 2 hours, and secondary
antibodies for 1 hour. Tissue was then exposed to DAPI for 5 minutes, mounted on the
slides and cover slipped with Prolong Glass.
Digital images were acquired through the Zeiss Axio Scan Z.7 digital slide scanner
at 20X magnification and 12 Z-stacks. Figures were captured using HALO software
(v3.3.2541.345, Indica Labs, Albuquerque, NM). Analysis was done by outlining the
regions of interest in the HALO software and quantifying the positive pixels. Regions of
interest included cortex, retro-splenial cortex hippocampus, CA1, CA2 and CA3 and DVC,
and were defined by using Allen Mouse Brain Reference Atlas.
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Table 4.1. Primary Antibodies
Primary antibodies
GLUT1
GLUT2
GLUT3
Pyruvate
Carboxylase
Pyruvate
Dehydrogenase
(ser 293)
NeuN
NeuN
GFAP
DAPI

Host
Rabbit
Rabbit
Rabbit

Company and catalog #
Abcam ab115730
Novus NBP2-22218
Alomone AGT-023

Dilution
1:200
1:200
1:200

Conditions
Overnight, RT
Overnight, RT
Overnight, RT

Rabbit

GeneTex GTX121987

1:200

Overnight, RT

Rabbit

EMD Milipore AP1062

1:200

Overnight, RT

Mouse
Rabbit
Chicken

Abcam ab279295
Abcam ab236870
GeneTex GTX85454
Novus NBP2-31156

1:1000
1:1000
1:2000
1:5000

1 hrs, RT
1 hrs, RT
2 hrs, RT
5 min, RT

Table 4.2. Secondary Antibodies
Secondary
antibodies
Goat anti-chicken
Goat anti-rabbit
Goat anti-mouse IgG

4.3.7

Fluorophore
Alexa 594
Alexa 488
Alexa 647

Company and
catalog #
A-11042
A-11034
A-21236

Dilution

Conditions

1:400
1:400
1:400

1hr, RT
1hr, RT
1hr, RT

Metabolomics Sample Preparation
Brains were removed aftrer microwave fixation, separated into regions of interest

(neocortex, hippocampus, DVC), and washed once with PBS, twice with diH 2O, blotted
dry, and snap frozen in Liquid nitrogen. The frozen tissues were pulverized to 10 μm
particles in liquid N2 using a Freezer/Mill Cryogenic Grinder (SPEX SamplePrep). Brain
regions were extracted with 1ml of 50% methanol in the grinder, while for muscle and liver
twenty milligrams of each pulverized tissue were extracted in 1ml of 50% methanol and
separated into polar (aqueous layer), and protein/DNA/RNA/glycogen pellet. The polar
fraction was dried at 10-3 mBar using a SpeedVac (Thermo) followed by derivatization.
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4.3.8

Pellet Hydrolysis
Hydrolysis of the protein/DNA/RNA/glycogen pellet was performed by first

resuspending the dried pellet in diH2O followed by the addition of equal parts 2N HCl.
Samples were vortexed thoroughly and incubated at 95C for 2 hours. The reaction was
quenched with 100% methanol with 40M L-norvaline (as an internal control). The sample
was incubated on ice for 30 minutes and the supernatant was collected by centrifugation
at 15,000rpm at 4C for 10 minutes. The collected supernatant was subsequently dried
for 4 hours by vacuum centrifuge at 10-3 mBar.
4.3.9

Sample Derivatization
Dried polar and glycogen samples were derivatized by the addition of 20mg/ml

methoxyamine hydrochloride in pyridine and sequential addition of N-methyl-trimethylsilyltrifluoroacetamide (MSTFA). Both reactions were incubated for 60 minutes at 60C with
thorough mixing in between addition of solvents. The mixture was then transferred to a vshaped amber glass chromatography vial and analyzed by GCMS.
4.3.10 GCMS Quantification
GCMS protocols were similar to those described previously [190,191], except a
modified temperature gradient was used for GC: Initial temperature was 130C, held for 4
minutes, rising at 6C/minutes to 243C, rising at 60C/minutes to 280C, held for 2
minutes. The electron ionization (EI) energy was set to 70 eV. Scan (m/z:50-800) and full
scan mode were used for metabolomics analysis. Automated Mass Spectral
Deconvolution and Identification System (AMDIS) software in combination with FiehnLib
metabolomics library was utilized to translate mass spectra into relative metabolite
abundance. Metabolites were matched for retention time and fragmentation pattern with
a confidence score of > 80 [192–194]. Data was further analyzed using the Data Extraction
for Stable Isotope-labelled Metabolites (DEXSI) software package [195]. Untargeted
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metabolomics data was normalized to total ion chromatogram and performed as described
in Young et al [196]. For glucose tracer raw data was exported and corrected for natural
abundance was done in IsoCorrectoR [197]. Fractional enrichment of each metabolite was
calculated as the relative abundance of each isotopologue relative to the sum of all other
isotopologues. Mean enrichment was calculated as sum of fractional enrichment of
labeled isotopologues (m+1, m+2, m+3…). For principal component analysis and pathway
impact analysis the online tool Metaboanlyst was used (https://www.metaboanalyst.ca/).
Data was was auto-scaled and log transformed.
4.3.11 Statistics
Statistical analyses were carried out using GraphPad Prism, student t-test. All
numerical data are presented as mean ± SEM. A P-value less than 0.05 was considered
statistically significant.

4.4
4.4.1

Results
Pooled metabolomics analysis of brain regions in a mouse model of T1DM
T1DM is a peripheral disease that is characterized by the lack of insulin production

and persistent high circulating blood glucose. To study the impact of T1DM on brain
glucose metabolism, we utilized the STZ model of insulin impairment and hyperglycemia
in mice and performed untargeted analysis of metabolite pools using GCMS. Mice were
randomly assigned to two groups (n=8), one that was injected intraperitoneally (IP) with
vehicle (citric acid, CA), and another with a single dose of STZ (200mg/kg) to induce
artificial hyperglycemia for 14 days to mimic T1DM (Fig 4.1A-B). Both cohorts of mice were
euthanized and fixed by microwave fixation followed by surgical resection of multiple brain
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regions (DVC, hippocampus, and neocortex) as well as peripheral organs (muscle and
liver). We observed increases only in glucose and leucine across all brain regions.
To understand the difference or similarities in our large data set we first carried out
an unsupervised principal component analysis (PCA). The role of PCA is to reduce the
number of variables of a data set while preserving as much information as possible. It is
a statistical tool to allow us to look at difference and similarities of large data sets. Each
dot represents a biological replicate for the particular group, with shading indicating the
95% confidence interval of the data set. Overlap in the data sets indicates metabolic
similarity, while distance indicates metabolic diversity. Our data shows that DVC is
metabolically different from the other brain regions, and T1DM drives metabolic
reprogramming differently (Fig 4.1).

Figure 4.1 PCA of mouse brain regions from a model of T1DM.
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To understand which metabolites, drive the metabolomic reprogramming across
the regions, we evaluated changes in each metabolite and changes within pathways.
Utilizing untargeted metabolomics we found that glucose concentration was significantly
elevated across all regions but glycogen and glucose-6-phosphate remained unchanged
with hyperglycemia only in DVC (Fig. 4.2C-D). Interestingly, pyruvate and lactate were
unchanged across all regions indicating that hyperglycemia does not affect anaerobic
cellular respiration. Intermediates of the tricarboxylic acid (TCA) malate and fumarate are
significantly decreased with hyperglycemia only in DVC, suggesting that hyperglycemia in
DVC preferentially affects TCA cycle. Furthermore, we observed a significant decrease in
glutamate across all regions while glutamine and GABA were unchanged, suggesting
neurotransmitter regulation disturbance (Fig. 4.2C-D). We observed changes in multiple
glycolytic and TCA cycle metabolites in the liver, but not in muscle, where the only major
difference was that T1DM increased glucose and leucine while decreasing lactate and
pyruvate (Fig. 4.3). Collectively, our data suggest that the DVC has a unique metabolomic
profile and that STZ-induced hyperglycemia mouse model predominately impacts TCA
metabolites in the DVC.
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Figure 4.2 Pooled metabolomics analysis of mouse brain from a model of T1DM
using high power focused microwave fixation (HPFM).
(A) Schematic of the experimental design. 6-week-old mice were injected with either
vehicle or 200mg/kg of streptozotocin (STZ) to induce hyperglycemia. After 14 days mice
were fasted for 3 hrs and euthanized by HPFM. Brain regions were then dissected, flashfrozen, and analyzed by GCMS. (B) Blood glucose levels measured by hand-held
glucometer in vehicle and T1DM mice after 14 days of hyperglycemia (n=8 biological
replicates per treatment). (C) Pathway analysis (performed by Metaboanalyst) of
neocortex (CTX), dorsal vagal complex (DVC), and hippocampus (HIPP) brain regions
between vehicle treated and T1DM mice. (D) Representative metabolite levels from
glycogen metabolism, glycolysis, and TCA cycle between vehicle and T1DM. Values are
presented as mean  SEM (n=6-8 biological replicates), *p<0.05, **p<0.01, ***p<0.001,
#

p<0.0001, analyzed by student t-test.
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Figure 4.3 Pooled metabolomics analysis of skeletal muscle (SKM) and liver from
a model of T1DM using high power focused microwave fixation (HPFM).
(A) Pathway analysis (performed by Metaboanalyst) of SKM and liver between vehicle
and T1DM. (B) Partial Least Squares-Discriminant Analysis (PLS-DA) of SKM and liver
metabolites between vehicle and T1DM animals (n=6-8). (C) Representative metabolite
levels from glycogen metabolism, glycolysis, and TCA cycle between vehicle and T1DM.
Values are presented as mean  SEM (n=6-8 biological replicates), *p<0.05, **p<0.01,
***p<0.001, #p<0.0001, analyzed by student t-test. G6P: glucose 6-phosphate, PEP:
phosphoenolpyruvate, AMP: adenosine phosphate
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4.4.2

Tracing 13C6-glucose metabolism in the brain of a mouse model of T1DM
Metabolic pathways are interconnected within a cell and metabolite pools can be

replenished through different metabolic substrates [186]. The TCA cycle metabolite pools
can be replenished from glucose, glutamine, and fatty acid metabolism. Therefore, pooled
metabolomics analysis does not fully illuminate unique substrate metabolism such as
glucose. T1DM is primarily a disease of hyperglycemia; therefore it is crucial to define the
glucose contribution to different metabolite pools. To assess whether there are differences
in glucose metabolism between vehicle and STZ treated mice we performed an additional
animal experiment with vehicle (citric acid) and STZ. Stable isotope tracing was performed
by delivery of 13C6-glucose through oral gavage and collection of brain regions (neocortex,
hippocampus and DVC) as well as muscle and liver at either 30 min or 2 hours post
gavage (Fig 4.4A-B). Similar to above, all cohorts of mice were euthanized and fixed in
situ with focused microwave and followed by brain regional dissection and peripheral
organ extraction. We observed significant decreases in glucose enrichment in central
carbon metabolites and de novo synthesized amino acids. This phenotype was consistent
across the neocortex, hippocampus, and the DVC for both time points (Fig. 4.4C-E, Fig.
4.5) as well as in peripheral organs (Fig. 4.6). Further, M2 and M3 isotopologues of citrate,
malate, fumarate, glutamine, glutamate, and aspartate all exhibit a decrease with
hyperglycemia compared to the vehicle at both time points (Fig. 4.4C-E, Fig. 4.5). This
suggests down-regulation of pyruvate dehydrogenase and pyruvate carboxylase activity
in STZ-induced hyperglycemia (T1DM) in multiple brain regions.
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Figure 4.4 Stable isotope labeling in the brain of a mouse model of T1DM at 2 hrs.
(A) Schematic of the experimental design. 6-week-old mice were injected with either
vehicle or 200mg/kg of streptozotocin (STZ) to induce hyperglycemia. After 14 days mice
were fasted for 3 hours, gavaged with 13C6-glucose and euthanized by high power fixation
microwave (HPFM). Brain regions were then dissected, flash-frozen, and analyzed by
GCMS. (B) Blood glucose levels were measured by hand-held glucometer before fasting,
before tracer gavage delivery, and before microwave fixation (n=8). (C-E) Representative
isotopologue for M6 of glycogen, glucose, and, M2 of citrate, aKG fumarate, malate,
glutamate, glutamine, GABA, aspartate and serine, and M3 of 3PG, pyruvate, lactate,
citrate, aKG, fumarate, malate, glutamate, glutamine, GABA, aspartate and serine for
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three brain regions, neocortex (CTX) (C), dorsal vagal complex (DVC) (D), and
hippocampus (Hipp) (E) of T1DM animals. Values are presented as mean  SEM (n=6-8
biological replicates), *p<0.05, **p<0.01, ***p<0.001, #p<0.0001, analyzed by student ttest. 3PG:3-phosphoglyceric acid, aKG: alpha-ketoglutarate.
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Figure 4.5 Stable isotope labeling in the brain of a mouse model of T1DM using
HPFM at 30 min.
Representative isotopologue for M6 of glycogen, glucose, and, M2 of citrate, aKG,
fumarate, malate, glutamate, glutamine, GABA, aspartate and serine, and M3 of 3PG,
pyruvate, lactate, citrate, aKG, fumarate, malate, glutamate, glutamine, GABA, aspartate
and serine for three brain regions, neocortex (CTX), dorsal vagal complex (DVC) and
hippocampus (HIPP) of T1DM animals. Values are presented as mean  SEM (n=4-7
biological replicates), *p<0.05, **p<0.01, ***p<0.001, #p<0.0001, analyzed by student ttest. 3PG:3-phosphoglyceric acid, aKG: alpha-ketoglutarate.
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Figure 4.6 Stable isotope labeling at 30 min and 2 hrs in T1DM mice in skeletal
muscle (SKM) (A) and liver (B).
Representative isotopologue for M6 of glycogen, glucose, and, M2 of citrate, fumarate,
malate, glutamate, glutamine, and aspartate, and M3 of pyruvate, lactate, citrate,
fumarate, malate, glutamate, glutamine, and aspartate for SKM and liver of T1DM animals.
Values are presented as mean  SEM (n=7-8 biological replicates), *p<0.05, **p<0.01,
***p<0.001, #p<0.0001, analyzed by student t-test.
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4.4.3

Downregulation of GLUT2, PDH, and PC proteins in unique neuronal cell layers.
The power of stable isotopic tracing is the direct assessment of metabolic enzyme

activities, through fractional enrichment, i.e. M2 and M3 isotopologues of citrate represent
PDH and PC activities, respectively. STZ-induced hyperglycemia mice show decreased
glucose enrichment in central carbon metabolites and reduced M2 and M3 isotopologues
of citrate (Fig 4.4). Therefore, we continued to evaluate glucose transporters, PDH, and
PC protein expressions in cortical and hippocampal regions using immunofluorescence
(IF). First, we performed IF on GLUT1, GLUT2, and GLUT3 glucose transporters that
have been shown to be increased with hyperglycemia in peripheral tissues [198–200]. Our
hypothesis was that glucose transporters would be decreased, as we have shown with
stable isotopic tracing that T1DM results in hindered glucose incorporation in all regions
of the brain across all central carbom metabolism pathways. We did not observe
significant changes in GLUT1 and GLUT3 expression in different brain regions (Fig 4.8).
However, GLUT2, a neuronal glucose transporter, showed a 15% to 70% decrease across
cortical/hippocampal regionals and the DVC (Fig. 4.9D). We saw a similar decrease in
PDH and PC protein by IF in cortical regions and the DVC (Figure 4.8L and Fig. 4.9H).
Interestedly, CA3 neuronal layer of the hippocampus was the only sub-region affected by
hyperglycemia, while CA1 and CA2 layers show no differences in protein expression
between PC and PDH assessed by IF (Figure 4.8B and Fig. 4.9). Collectively, these data
suggest STZ-induced hyperglycemia results in downregulation of metabolic enzymes
PDH and PC at the protein level, as well as glucose transporter downregulation that
correlate with glucose hypometabolism of the brain.
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Figure 4.8 Immunofluorescent analysis of GLUT3, GLUT1 and PDH expression in
neocortex (CTX), hippocampus (HIPP) and brainstem (BS) in a mouse model of
T1DM.
(A-D) 20m coronal sections of the mouse brain were stained with GLUT3 (green) and
NeuN (red) and quantified in the CTX (A), HIPP (B), and BS (C). Zoomed-in images are
shown for the retro-splenial cortex (RS), Cornu Ammonis 3 (CA3) of HIPP, and dorsal
vagal complex (DVC) of BS. (D) Quantification of % positive pixels for Glut3 using HALO
software, area of interest include whole cortex, RS (zoomed in), whole HIPP, CA1-CA3
(zoomed in), and DVC following mouse brain atlas, and quantification was run for positive
pixels in each channel and colocalization. Values are presented as mean  SEM (n=4
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biological replicates), *p<0.05, **p<0.01, ***p<0.001, analyzed by student t-test. (E-H)
20m coronal sections of the mouse brain were stained with GLUT1 (green) and DAPI
(blue) and quantified in the CTX (E), HIPP (F), and BS (G). Zoomed-in images are shown
for the RS, CA3 of HIPP, and DVC of BS. (H) Quantification of % positive pixels for GLUT1
using HALO software, area of interest including whole neocortex, RS (zoomed in), whole
HIPP, CA1-CA3 (zoomed in), and DVC following mouse brain atlas, and quantification
was run for positive pixels in each channel and colocalization. Values are presented as
mean  SEM (n=4 biological replicates), *p<0.05, **p<0.01, ***p<0.001, analyzed by
student t-test. (I-L) 20m coronal sections of the mouse brain were stained with PDH (red)
and quantified in the CTX (I), HIPP (J), and BS (K). Zoomed-in images are shown for the
retro-splenial cortex (RS), CA3 of HIPP, and DVC of BS. (L) Quantification of % positive
pixels for PDH using HALO software, area of interest include whole cortex, RS (zoomed
in), whole HIPP, CA1-CA3 (zoomed in), and DVC following mouse brain atlas, and
quantification was run for positive pixels in each channel and colocalization. Values are
presented as mean  SEM (n=4 biological replicates), *p<0.05, **p<0.01, ***p<0.001,
analyzed by student t-test. Scale bars are either 1mm, 500m, or 100m. GLUT1-glucose
transporter 1, GLUT3-glucose transporter 3, PDH-pyruvate dehydrogenase.
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Figure 4.9 Immunofluorescent analysis of GLUT2 and PC expression in neocortex
(CTX), hippocampus (HIPP) and brainstem (BS) in a mouse model of T1DM.
(A-D) 20m coronal sections of the mouse brain were stained with GLUT2 (green) and
NeuN (red) and quantified in in the CTX (A), HIPP (B), and BS (C). Zoomed-in images are
shown for the retro-splenial cortex (RS), Cornu Ammonis 3(CA3) of HIPP, and dorsal
vagal complex (DVC) of BS. (D) Quantification of % positive pixels for GLUT2 using HALO
software, area of interest include whole cortex, RS (zoomed in), whole HIPP, CA1-CA3
(zoomed in), and DVC following mouse brain atlas, and quantification was run for positive
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pixels in each channel and colocalization. Values are presented as mean  SEM (n=4
biological replicates), *p<0.05, **p<0.01, ***p<0.001, analyzed by student t-test. (E-H) 20
m coronal sections of the mouse brain were stained with pyruvate carboxylase (PC)
(green) and NeuN (red) and quantified in in the CTX (E), HIPP (F), and BS (G). Zoomed
in image are shown for the RS, CA3 of HIPP, and DVC of BS. (H) Quantification of %
positive pixels for PC using HALO software, area of interest including whole neocortex,
RS (zoomed in), whole HIPP, CA1-CA3 (zoomed in), and DVC following mouse brain
atlas, and quantification was run for positive pixels in each channel and colocalization.
Values are presented as mean  SEM (n=4 biological replicates), *p<0.05, **p<0.01,
***p<0.001, analyzed by student t-test. Scale bars are either 1mm, 500m, or 100m. PC:
pyruvate carboxylase, GLUT2: glucose transporter 2.
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4.5

Discussion
T1DM affects about 20 million people worldwide and chronic hyperglycemia leads

to micro/macro-vascular diseases, retinopathy, peripheral neuropathy, and liver disease
[201]. Recent reports have highlighted the impact of T1DM on brain glucose metabolism
as T1DM patients have increased risk of developing late-onset dementia [202]. Glucose
hypometabolism is characterized by reduced uptake of 2-fluorodeoxyglucose (FDG),
imaged by Positron Emission Tomography (PET), and is a common pathological feature
shared among multiple neurological disorders such as Alzheimer's disease (AD) [205],
Parkinson’s disease [206], temporal lobe epilepsy [207], as well as inherited pediatric
neurodegenerative diseases [208].
We interrogated the changes in pooled brain metabolome and more specifically,
glucose metabolism using 13C6-glucose isotopic tracing in the STZ mouse model of T1DM.
We observe reginal changes in pooled metabolites. Glucose was increased across all
regions, while glycogen and glucose-6-phosphate was increased in the neocortex and
hippocampus but not in DVC. Pyruvate and lactate were unchanged across all regions
indicating that hyperglycemia does not affect anaerobic cellular respiration. Intermediates
of the tricarboxylic acid (TCA) malate and fumarate are significantly decreased with
hyperglycemia only in DVC, suggesting that hyperglycemia in DVC preferentially affects
TCA cycle. Furthermore, we observed a significant decrease in glutamate across all
regions while glutamine and GABA were unchanged, suggesting neurotransmitter
regulation disturbance (Fig. 4.2C-D).
We then performed 13C-glucose tracing through oral gavage. We observed glucose
hypometabolism in multiple regions of the brain. Decreased enrichment of glycolytic and
TCA cycle isotopologues were noted in multiple regions of the brain including cortex,
hippocampus, and DVC. These data are in agreement with multiple previous reports
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showing brain glucose hypometabolism in T1DM patients [203], impaired hepatic glycogen
accumulation [50–53], glycogenolysis [62,204], and increased hepatic glucose production
[54–57].
Furthermore, while glucose metabolism is decreased with T1DM, because
glycogen remained unchanged in the DVC it is suggesting alternative fuel sources are
being utilized by the DVC in T1DM mice. Within the DVC, isotopic enrichment of glycogen,
glucose and citrate remained unchanged. However, 13C6 enrichment in the DVC of T1DM
animals was significantly decreased in pyruvate and lactate, as well as fumarate, malalte,
glutamate, glutamine, GABA and aspartate, suggesting glucose is preferentially oxidized
via the TCA cycle. It is worth noting that the DVC is not enclosed within the blood-brain
barrier and could have alternative metabolic controls compared to the cortex and
hippocampus.
Finally, we have shown that PC and PDH are neuronally expressed enzymes in
the brain and significantly downregulated with hyperglycemia. In addition, we have shown
that GLUT2 is downregulated across all region (neocortex, hippocampus and DVC).
Collectively, these results establish that hyperglycemia drives metabolic reprogramming
in the brain and highlights the need to continue investigating how peripheral glucose
concentration affects the brain metabolome.
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CHAPTER 5. GENERAL DISCUSSION
5.1
5.1.1

Review of major findings
High-powered focused microwave to study brain metabolism
In Chapter 2, we showed that high-power focused microwave (HPFM) fixation

preserves the glycolytic metabolome better than traditional decapitation followed by cryopreservation of brain tissue and is compatible with stable isotopic tracing. We have also
shown that HPFM does not change the isotopic enrichment, suggesting that flux was
unchanged as the rate of production to utilization was the same.
5.1.2

Systemic glucose regulation by an inhibitory brainstem circuit in a mouse model
of T1DM
In Chapter 3, we demonstrated that inhibiting GABAergic neurons was sufficient

to lower blood glucose levels in a hyperglycemic mouse model, while activating
GABAergic neurons in normoglycemic animals was sufficient to raise blood glucose levels.
Interestingly, activating GABAergic neurons in hyperglycemic animals and inhibiting
GABAergic neurons in normoglycemic animals resulted in no change in blood glucose
levels. We also showed that observed changes in peripheral glucose concentration were
mediated by the vagus nerve as administration of MSA, a muscarinic acetylcholine
receptor antagonist that cannot cross the blood-brain barrier, abolished the CNO-driven
change in blood glucose levels.
5.1.3

Hyperglycemia driven metabolic reprogramming in the brain
In Chapter 4, we demonstrated that T1DM increases glucose and leucine

concentration across all brain regions studied. Glycogen and glucose 6-phosphate were
only increased in cortex and hippocampus, but not DVC. We observed decreased
concentration of glutamate across all regions of the brain but no change in glutamine or
GABA levels. However, to our surprise, the vast majority of metabolites analyzed did not
79

change in abundance. To understand the changes in flux between different pools of
metabolites we utilized

13

C6 tracing and we were able to demonstrate a glucose hypo-

metabolic phenotype in the brain. Immunofluorescence labeling revealed a decrease in
the expression of the GLUT2 transporter, and colocalization indicated neuronal-specific
expression. Notably, both isotopic tracing and immunofluorescence showed a decrease
in activity and expression of PC, and PDH enzymes, further indicating a hypometabolic
phenotype.

5.2

Hyperglycemia’s effect on the expression of glucose transporters in the brain
The majority of brain glucose uptake is insulin-independent [213] and relies on the

concentration gradient as the major driving force across blood-brain barrier. When the
concentration of glucose increases in the plasma it stands to reason that it will increase in
the brain interstitium as well, and our data supports that notion. The majority of the glucose
is transported across the BBB by the GLUT1 transporter and previous studies of GLUT1
protein expression have shown a decrease [78,214] or no change in GLUT1 expression
in T1DM [76,215,216]. Our immunofluorescent analysis showed no change in GLUT1
between T1DM and vehicle mice in the neocortex, hippocampus, and DVC. This is not
surprising given that studies that did find differences were utilizing vessel extraction and
not IF. Given that the concentration of glucose within the brain regions of T1DM mice was
significantly increased, we expected no change with GLUT1 transporter. Neuronal GLUT3
protein abundance has been shown to increase with STZ-induced hyperglycemia but only
in hippocampus [217]. Based on our immunofluorescence analysis of GLUT3 in the brain
and brainstem we have shown no changes in GLUT3 expression; however, we observed
a profound decrease in GLUT2 expression in the cortex, hippocampus, and DVC. It has
been reported that GLUT2 is capable of glucose sensing [161,218–220], and therefore we
speculate that the decrease in GLUT2 could be an adaptive response of the body to
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prevent excessive glucose uptake, as glucotoxicity could lead to apoptosis [221].
Furthermore, if GLUT2 is responsible for glucose sensing in the brain, the downregulation
of the transporter could potentially trick the brain into sensing that the glucose levels are
still within normal range, and therefore allow the brain to continue with normal function,
despite the high levels of glucose. Lastly, GLUT2 is known to be neuronal, which we
confirmed with immunofluorescence colocalization with NeuN. Therefore, the impact of
hyperglycemia would be the greatest in neuronal glucose metabolism and could explain
the cognitive deficits that are present with T1DM [202,222,223]. Given that DVC is not
under the blood-brain barrier and has a significant decrease in GLUT2 expression with
T1DM it would stand to reason that increase in peripheral glucose levels with T1DM would
not affect glucose utilization during T1DM in the DVC, which is exactly what we have
demonstrated with stable isotopic tracing; glucose and glycogen utilization in the DVC with
T1DM remains unchanged.

5.3

Role of glucose in anabolic reactions in hyperglycemia
Metabolism can be described as a combination of two opposing processes,

anabolism and catabolism. Energy harvested during catabolism is utilized in anabolic
reactions. Glucose-derived neurotransmitters include acetylcholine, glutamate, and GABA
[28]. We have shown that hyperglycemia results in decreased generation of glutamate
and GABA in cortex, DVC and hippocampus. Therefore, one of the major ways
hyperglycemia affects the production of neurotransmitters is through hypometabolism of
glucose which results in lower flux of key neurotransmitters derived from glucose.
Interestingly, while the total pool of glutamate was decreased with T1DM, there were no
changes in GABA or glutamine, suggesting the utilization of alternative pathways for the
generation of glutamate, such as glutamine or fatty acids. Furthermore, we report in
Chapter 3 that the changes in peripheral blood glucose levels are driven through
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glutamate-dependent GABA signaling, but we have not observed an increase in GABA
with metabolomics approaches. One way to reconcile that difference is the fact that in
Chapter 3 we focused on GABA as a signaling molecule and have reported
hyperglycemia’s effect on electrical activity of the DVC microcircuit, while metabolomics
analysis does not discriminate between GABA neurotransmitter packed into vesicle ready
to act onto receptor or GABA metabolite within cellular compartments.

5.4

Origin of glucose hypometabolism
Hyperglycemia results in a decrease in GCK expression in the liver [60] and in the

brainstem [224,225]. It has been demonstrated that GCK is involved in glucose sensing
[161,225–227]. We have shown that hyperglycemia results in increased glucose in all
brain regions and increased glycogen levels in the cortex and hippocampus, but not the
DVC. Of note, despite the high levels of glucose, de novo synthesis of TCA cycle
intermediates is decreased. Glucose 6 phosphate was only increased in the cortex and
hippocampus, not DVC, suggesting an increase in glucose entry just in the cortex and
hippocampus but not in DVC, as the conversion of glucose into glucose 6-phosphate traps
the glucose inside of the cell [228]. It could be speculated that once glucose reaches a
high concentration in the DVC, GCK downregulation results in the maintenance of a
relatively similar total concentration of G6P, suggesting that the origin of glucose
hypometabolism in the DVC is possibly due to GCK. Furthermore, we have shown a
significant decrease in the expression of PC, a key enzyme in the irreversible
carboxylation of pyruvate into oxaloacetate in cortex and CA3, but not in the DVC. Given
the reduction in the PC in cortex and CA3 the reduced glucose utilization as seen in
isotopic tracing (significant decrease in the enrichment of
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C6 across all TCA cycle

intermediates) was expected because the PC is gate keeper in replenishing TCA cycle
intermediates. However, in the DVC, PC was unchanged and glucose utilization was also
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unchanged (no changes in the enrichment of 13C6 in glucose), which was expected as well
because PC is also a key enzyme in gluconeogenesis.

5.5

Glucose as a signaling molecule
Communication in the brain between different cells, as well as maintenance of

overall homeostasis, is achieved by neurotransmitters and hormones. The primary role of
glucose is that of an energy source and building block, but another important one is in
terms of signaling [229]. Therefore, alterations in glucose concentration not only have a
profound effect on metabolism and homeostasis but also on an array of processes where
glucose serves as a signaling molecule both in the periphery and the brain. For example,
one of the processes in the CNS where glucose plays a key signaling role is in glucose
sensing in the brainstem nuclei which has been described in depth [162,176–178].
Glucose sensing is impaired with hyperglycemia. Neuronal activity is dependent on
glucose concentration. Therefore, changes in the concentration of glucose, viewed in
terms of energy homeostasis, can directly lead to functional changes in neuronal activity.

5.6

Role of glycogen in T1DM
Glycogen levels are very heterogenous among the tissues, with the liver having

100 times more glycogen than the brain [230]. Glycogen plays important role in brain
physiology as it is involved in maintaining the proper neuronal function and is involved in
learning and memory [231]. Our data shows an increase in the total pool of glycogen and
a decrease in glycogen production with
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C6 labeled glucose in the cortex and

hippocampus but not in the DVC. This suggests that excess glucose that we observed
with T1DM in all brain regions analyzed is not converted to a storage form of glycogen in
the DVC, further suggesting a similar rate of glycogenesis in the DVC between control and
T1DM animals. This is of importance for the metabolism of the DVC as we also shown no
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change in pyruvate and lactate, therefore indicating that the excess glucose in the DVC is
oxidized through TCA cycle.

5.7

Does T1DM drive brain glucose hypometabolism, or is the glucose hypometabolism driving T1DM?
Metabolome changes and metabolic stress precede the appearance of the first

islet autoantibodies [42]. We here investigated the 14 days time point of T1DM, but it
should be noted and considered if changes in the metabolome drive the pathophysiology
of T1DM. As proposed by Schwartz et al., a more complete understanding of glucose
homeostasis involves insulin-independent glucose disposal under the control of the CNS
[88]. In that perspective, hyperglycemia is a result of the failure of the islet to produce
insulin and lower blood glucose via insulin-dependent pathways, as well as altered activity
of neuronal nuclei in the hypothalamus and brainstem, resulting in insulin-independent
failure to control glucose production. DVC is the last modulation point of the CNS capable
of altering hepatic glucose production. It is possible that maybe metabolites like glycogen
or glucose-6-phosphate are used as signaling molecules to alter hepatic glucose
production. In that case, we have shown that with T1DM in the DVC the levels of glycogen
and glucose-6-phosphate are unchanged compared to other brain regions and are
potentially the culprit for dysregulation of hepatic glucose. If hyperglycemia alters the
CNS’s capacity to regulate hepatic glucose production, then the potential therapeutic
target should be restoring the glucose hypometabolism phenotype in the brain and thus
restoring the CNS’s capacity to regulate hepatic glucose production.

5.8

Future directions
While we demonstrated the effect of T1DM on the metabolome of different brain

regions and peripheral organs and the impact of altering GABAergic neurons in the DVC
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has on the whole blood glucose levels, we were unable to pinpoint whether the changes
in altered activity are driven through changes in the metabolome. In addition, while we
showed a glucose hypometabolic phenotype in the brain with T1DM, we were unable to
pinpoint specific changes in different cell types. Future studies should focus on isolating
single cell types through fluoresce-activated cell sorting (FACS) or magnetic separation
methodologies after microwave fixation, to define the cell type-specific brain metabolism
in healthy and diseased tissue. It would also be of interest to test whether HPFM is
compatible with new single-cell technologies such as matrix-assisted laser desorption
ionization (MALDI) mass spectrometry imaging [144], single cell RNAseq [145], and
spatial proteomics analyses [146,147]. Furthermore, it would be of great importance to
understand if hyperglycemia affects differently glutamatergic and GABAergic neurons in
the brains, and especially in the DVC. This could be done by utilizing cell culture and
MALDI or GCMS. Understanding how each cell type within different brain regions is
affected by hyperglycemia would allow for therapeutic approaches that potentially only
target a subset of cells which could restore brain metabolic homeostasis.
We choose to look at 14 days after the onset of hyperglycemia, a time point in
which we have had only 5% mortality and mice consistently have elevated blood glucose
(above 550mg/dL). At this time point, blood-brain barrier permeability is still intact [232],
and therefore the effects seen are due to hyperglycemia and not complications with micro
or macro vasculature. Given the glucose hypometabolism results, it would be of interest
to conduct metabolomic experiments across different time points to identify which of the
central carbon pathways is affected first and leads to the downstream effects on glucose
hypometabolism.
In the future, the addition of T2DM in both sets of experiments would further our
understanding of similarities/differences between T1DM and T2DM, including a cohort of
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animals treated with insulin to understand which of the metabolic phenotypes we observed
were rescuable. It would be of importance not only to look at insulin delivered peripherally,
but to the brain (either intranasally or ICV). Insulin’s role as a neurotransmitter has only
started to be elucidated [213]. Also, GLUT1 staining was only performed on one isoform,
the heavily glycosylated form found in endothelial cells (52kDa), and not the lightly
glycosylated form found in astrocytes [233].

5.9

Final Conclusion
The combined findings of this body of work show that modulating the activity of

GABAergic neurons in the DVC can alter peripheral glucose levels, and the metabolome
of the DVC undergoes reprogramming with T1DM, as seen in a hypometabolism
phenotype. Interestingly the utilization of glycogen and glucose in the DVC, as measured
by stable isotopic tracing, remained unchanged, suggesting the possible target for
intervention and connection to hepatic gluconeogenesis. In addition, these data warrant
exploring therapeutic interventions beyond insulin administration for T1DM, specifically
focusing on hindering hepatic gluconeogenesis. The experiments outlined in this thesis
are novel in several ways. First, there are no other published studies looking at the
metabolome of multiple brain regions and peripheral organs to assess the abundance as
well as the metabolic flux of major metabolic pathways including glycolysis, tricarboxylic
acid cycle, and neurotransmitter synthesis. Secondly, we performed an in-depth
characterization of high-power focused microwave fixation, highlighting its compatibility
with isotopic tracing. Next, we have shown different metabolic footprints between areas of
the brain under the blood-brain barrier (cortex and hippocampus) and areas outside of the
blood-brain barrier (DVC).

Lastly, we employed DREADDs approach to selectively

change the activity of GABAergic neurons and show that neuronal modulation affects
whole-body glucose levels. The exact role that peripheral metabolic changes play in
86

affecting neuronal activity and how hyperglycemia can drive those has yet to be
elucidated.
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